FXR partial agonist containing piperidine structure as well as preparation method and application of FXR partial agonist

By developing partial FXR agonists containing piperidine structures, the problem of serious side effects of existing FXR complete agonists in the treatment of NASH is solved, and more efficient and safer FXR agonists are achieved, which significantly improves liver steatosis and blood lipid disorders. .

CN118955358APending Publication Date: 2024-11-15GUILIN MEDICAL UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410878974.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-02
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The existing FXR complete agonists have serious side effects in the treatment of non-alcoholic steatohepatitis (NASH), which limits its clinical application, and the efficacy and safety of existing FXR partial agonists still need to be improved.

Method used

A partial agonist of FXR containing piperidine structure and its preparation method were developed. Through specific compound structures and synthetic routes, the selectivity and activity of partial agonist of FXR was improved, the toxicity to the liver was reduced, and the NASH was enhanced. therapeutic effect.

Benefits of technology

The partial agonist of FXR significantly reduced liver fat content, reduced ALT levels, reduced itching side effects, improved the therapeutic effect on NASH, and had significant improvements on liver steatosis and blood lipid disorders in HepG2 cells and mouse models.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118955358A_ABST
    Figure CN118955358A_ABST
Patent Text Reader

Abstract

The invention provides a farnesoid X receptor (FXR) partial agonist containing a piperidine structure as shown in a general formula (I) or (II), a preparation method of the farnesoid X receptor (FXR) partial agonist, and application of a pharmaceutical composition containing the farnesoid X receptor (FXR) partial agonist as a medicine for preventing or / and treating FXR-mediated diseases or symptoms, the diseases comprise non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, primary biliary cholangitis, lipid metabolism disorder and the like. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of new drug design and synthesis, in particular to an FXR partial agonist containing a piperidine structure and a preparation method and use thereof. Background Art

[0002] Nonalcoholic steatohepatitis (NASH) is an aggressive form of nonalcoholic fatty liver disease (NAFLD), characterized histologically by fatty degeneration of the liver, ballooning of hepatocytes, inflammation and damage, and in severe cases, liver fibrosis. If NASH is not controlled, it may further develop into cirrhosis, liver failure, and eventually liver cancer. It is estimated that the prevalence of NASH in the general population is 1.5% to 6.45%. Despite the high prevalence and significant disease burden, there is currently only one drug on the market (Resmetirom, a thyroid hormone beta receptor agonist) approved by the U.S. Food and Drug Administration for the treatment of NASH in March 2024. Therefore, exploring effective drugs for the treatment of NASH has broad application prospects.

[0003] Farnesoid X receptor (FXR) is a member of the nuclear receptor superfamily and is highly expressed in the liver, small intestine, kidney, and adrenal gland. It has been confirmed that FXR is involved in regulating metabolic pathways that are highly related to metabolic diseases, such as bile acid, cholesterol, lipids, and glucose. Therefore, FXR is a highly potential drug target in NAFLD, NASH, cholestasis, liver fibrosis, primary biliary cholangitis, and lipid metabolism disorders (Chen J, et al. Elife. 2024, 13: RP91438; Adorini L, et al. J Hepatol, 2023, 79 (5), 1317–1331; Zhou S, et al. Biomed Pharmaco, 2022, 154: 113577). At present, many FXR agonists have made progress in anti-NASH clinical trials and have shown good efficacy in slowing down the progression of liver steatosis, inflammation, and fibrosis. FXR agonists mainly include two categories: steroidal and nonsteroidal. Steroidal FXR agonists include obeticholic acid (OCA) and chenodeoxycholic acid. OCA is a full FXR agonist and has been approved for the treatment of primary biliary cholangitis. However, its indication for non-alcoholic fatty hepatitis was terminated in Phase III clinical trials, mainly because of its serious adverse reactions, such as skin itching, increased low-density lipoprotein cholesterol (LDL-C) and reduced high-density lipoprotein cholesterol (HDL-C). GW4064 is the first non-steroidal potent full FXR agonist discovered by GlaxoSmithKline. It has high FXR target selectivity and in vitro activity. It cannot be developed into a drug due to its limited solubility, potential toxicity, UV instability and poor pharmacokinetics. In addition, clinical trials of non-steroidal full FXR agonists such as Tropifexor, Cilofexor, and TERN-101 also showed varying degrees of side effects.

[0004] In clinical trials, systemic activation of FXR can lead to a variety of adverse side effects, such as itching, imbalance in cholesterol homeostasis, gastrointestinal effects, and increased risk of liver decomposition, which severely limits the application of FXR full agonists in the treatment of NASH. Reducing these side effects is crucial to the continued development of FXR agonists. To this end, FXR partial agonists are increasingly considered a better choice (Jiang L, et al. Comput Struct Biotechnol J. 2022, 20: 1227-1228; Shim S, et al. J Med Chem, 2022, 65: 9974-10000). Reported FXR partial agonists include LY256217531 and Nidufexor. Nidufexor has a maximum efficacy of 57% relative to GW4064 and can selectively activate FXR target genes. In a Phase II trial of NASH patients, Nidufexor treatment significantly reduced liver fat content by approximately 30% and reduced ALT levels. Notably, only 29% of patients treated with 50 mg / day Nidufexor experienced mild to moderate pruritus (compared to 15% of patients receiving placebo), which was significantly lower than the 51% of patients treated with 25 mg / day OCA. These data suggest that FXR partial agonists may provide adequate efficacy for NASH treatment with a reduced incidence of side effects.

[0005] Therefore, the discovery of potential FXR partial agonists is of great significance for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Summary of the invention

[0006] The present invention provides a FXR partial agonist containing a piperidine structure, a preparation method and use thereof, and provides a broader idea for the application of the FXR partial agonist in the treatment of non-alcoholic fatty liver disease, non-alcoholic fatty hepatitis, cholestasis, liver fibrosis, primary bile duct sclerosis, primary biliary cholangitis, lipid metabolism disorders and other diseases.

[0007] To achieve the above object, the technical solution of the present invention is:

[0008] A compound having the general formula (I) or (II) or a pharmaceutically acceptable salt thereof:

[0009]

[0010] in:

[0011] R1 is selected from any one of the following groups: phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 4-chlorophenyl, 4-ethylphenyl, 4-methylphenyl, 4-fluorophenyl, 2-methoxyphenyl, 3-methoxyphenyl, 2,6-difluorophenyl, 3-methylphenyl, 1-naphthyl;

[0012] R2, R3, R5 and R6 are each independently selected from hydrogen, methyl or halogen;

[0013] R4 is selected from hydrogen, methyl, halogen, isopropyl or tert-butyl;

[0014] R7 is selected from any one of the following groups: 4-propylphenyl, 2-methoxyphenyl, 4-methoxyphenyl, 3,5-difluorophenyl, 2,5-difluorophenyl, 3,4-difluorophenyl, 3-fluorophenyl, 4-isopropylphenyl, 4-tert-butylphenyl,

[0015] Preferably, the above-mentioned compound or its pharmaceutically acceptable salt is selected from any one of the following compounds:

[0016]

[0017]

[0018] The present invention further provides a method for preparing the above-mentioned compound or a pharmaceutically acceptable salt thereof.

[0019] The method for preparing the compound of general formula (I) or a pharmaceutically acceptable salt thereof comprises the following steps:

[0020] A1. In an organic solvent, ethyl 4-aminophenylacetate of compound III and 3-fluorobenzyl bromide of compound IV-1 are reacted under alkaline conditions to obtain compound V-1

[0021] A2. Compound V-1 and Compound VI-1 under alkaline conditions Reaction to obtain compound VII-1

[0022] A3. Compound Ⅶ-1 is hydrolyzed in a solvent and alkaline conditions, and then acidified to obtain compound Ⅷ-1

[0023] A4. Compound VIII-1 undergoes an amidation reaction with compound IX piperidine-4-carboxylic acid ethyl ester to obtain a compound of formula (I) or a pharmaceutically acceptable salt thereof.

[0024] The preparation method of the compound of general formula (II) or its pharmaceutically acceptable salt comprises the following steps:

[0025] B1. In an organic solvent, ethyl 4-aminophenylacetate of compound III and compound IV-2 Reaction under alkaline conditions to obtain compound V-2

[0026] B2. Compound V-2 and compound VI-2 under alkaline conditions Reaction to obtain compound VII-2

[0027] B3. Compound Ⅶ-2 is hydrolyzed in a solvent and alkaline conditions, and then acidified to obtain compound Ⅷ-2

[0028] B4. Compound VIII-2 undergoes an amidation reaction with compound IX piperidine-4-carboxylic acid ethyl ester to obtain a compound of formula (II) or a pharmaceutically acceptable salt thereof.

[0029] Preferably, in step A1, the molar ratio of the compound III to the compound IV-1 is 1:1-1.5, the reaction temperature is 45-60°C, and the reaction time is 6-12h; the organic solvent is selected from one of anhydrous tetrahydrofuran, N,N-dimethylformamide, dichloromethane, and chloroform, and the alkaline condition is adjusted by adding one of potassium carbonate, sodium carbonate and triethylamine.

[0030] Preferably, in step A2, the molar ratio of the compound V-1 to the compound VI-1 is 1:1 to 1.5, the reaction temperature is 45 to 60° C., and the reaction time is 6 to 24 h; the alkaline condition is achieved by adding triethylamine;

[0031] In step A3, the solvent is one of anhydrous ethanol, methanol and tetrahydrofuran, the alkaline condition is achieved by adding sodium hydroxide or potassium hydroxide, the hydrolysis reaction temperature is 20 to 40° C., and the reaction time is 6 to 12 hours;

[0032] In step A4, the molar ratio of the compound VIII-1 to the compound IX is 1:1 to 1.5, the reaction temperature is 45 to 60°C, the reaction time is 8 to 12 hours, and the solvent used in the amidation reaction is selected from anhydrous tetrahydrofuran, N,N-dimethylformamide, dichloromethane and chloroform, and the selected condensation agent is 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate and N,N-diisopropylethylamine.

[0033] Preferably, in step B1, the molar ratio of the compound III to the compound IV-2 is 1:1-1.5, the reaction temperature is 45-60°C, and the reaction time is 6-12h; the organic solvent is selected from one of anhydrous tetrahydrofuran, N,N-dimethylformamide, dichloromethane, and chloroform, and the alkaline condition is adjusted by adding one of potassium carbonate, sodium carbonate and triethylamine.

[0034] Preferably, in step B2, the molar ratio of the compound V-2 to the compound VI-2 is 1:1 to 1.5, the reaction temperature is 45 to 60°C, and the reaction time is 6 to 24 hours; the alkaline condition is achieved by adding triethylamine;

[0035] In step B3, the solvent is one of anhydrous ethanol, methanol and tetrahydrofuran, the alkaline condition is achieved by adding sodium hydroxide or potassium hydroxide, the hydrolysis reaction temperature is 20 to 40° C., and the reaction time is 6 to 12 hours;

[0036] In step B4, the molar ratio of the compound VIII-2 to the compound IX is 1:1-1.5, the reaction temperature is 45-60°C, the reaction time is 8-12h, and the solvent used in the amidation reaction is selected from anhydrous tetrahydrofuran, N,N-dimethylformamide, dichloromethane and chloroform, and the selected condensation agent is 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate and N,N-diisopropylethylamine.

[0037] The preparation method of the compound of general formula (I) or its pharmaceutically acceptable salt is as follows:

[0038]

[0039] The preparation method of the compound of general formula (II) or its pharmaceutically acceptable salt, the preparation route is as follows:

[0040]

[0041] The present invention further provides a pharmaceutical composition, which comprises the compound having the general formula (I) or (II) or its pharmaceutically acceptable salt as described above, or the compound having the general formula (I) or (II) or its pharmaceutically acceptable salt prepared by the preparation method as described above, and a pharmaceutically acceptable carrier.

[0042] The present invention further provides the use of the above-mentioned compound or its pharmaceutically acceptable salt, or the compound having the general formula (I) or general formula (II) or its pharmaceutically acceptable salt prepared by the above-mentioned preparation method, or the above-mentioned pharmaceutical composition as a FXR partial agonist in the preparation of drugs for treating FXR-related diseases.

[0043] Preferably, the FXR-related disease is one or a combination of more than one of non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, cholestasis, liver fibrosis, primary biliary cholangitis, and lipid metabolism disorders.

[0044] The present invention provides a compound containing a piperidine structure or a pharmaceutically acceptable salt thereof, which can be used as a FXR partial agonist, and provides more possibilities for the application of the FXR partial agonist in the treatment of non-alcoholic fatty liver disease, non-alcoholic fatty hepatitis, cholestasis, liver fibrosis, primary biliary cholangitis, lipid metabolism disorders and other diseases.

[0045] The present invention uses the prepared derivative or its pharmaceutically acceptable salt, or its pharmaceutical composition as a FXR partial agonist for preparing drugs for treating FXR-related diseases, such as non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, cholestasis, liver fibrosis, primary biliary cholangitis, lipid metabolism disorders, etc. In vitro FXR agonist activity studies, HepG2 and L02 cell toxicity studies, HepG2 cell Oil Red O staining experiments, HepG2 cell triglyceride content tests, and in vivo anti-non-alcoholic steatohepatitis activity studies have confirmed that the compounds of the present invention have good farnesoid X receptor agonist activity and have the potential to prepare drugs for treating non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. BRIEF DESCRIPTION OF THE DRAWINGS

[0046] Figure 1 This is the test result of triglyceride (TG) content in HepG2 cells of compound 17.

[0047] Figure 2 This is the result of the HepG2 cell Oil Red O staining experiment of compound 17; wherein: Figure 2 a is the result of Oil Red O staining of HepG2 cells in the normal group. Figure 2 b is the result of Oil Red O staining experiment of HepG2 cells treated with compound 17 (0.05 μM); Figure 2 c is the result of Oil Red O staining experiment of HepG2 cells treated with compound OCA (10 μM); Figure 2 d is the experimental result of Oil Red O staining of HepG2 cells in the model group; Figure 2 e is the result of Oil Red O staining experiment of HepG2 cells treated with compound 17 (0.1 μM); Figure 2 f is the Oil Red O staining experimental results of HepG2 cells treated with V022-1200 (1 μM).

[0048] Figure 3 This is a schematic diagram of the effect of compound 17 on serum triglycerides (TG) in NASH mice.

[0049] Figure 4 This is a schematic diagram of the effect of compound 17 on serum cholesterol (TC) in NASH mice.

[0050] Figure 5This is a schematic diagram of the effect of compound 17 on serum low-density lipoprotein cholesterol (LDL-C) in NASH mice.

[0051] Figure 6 This is a schematic diagram of the effect of compound 17 on serum high-density lipoprotein cholesterol (HDL-C) in NASH mice.

[0052] Figure 7 This is a schematic diagram of the effect of compound 17 on alanine aminotransferase (ALT) in NASH mice.

[0053] Figure 8 This is a schematic diagram of the effect of compound 17 on aspartate aminotransferase (AST) in NASH mice.

[0054] Fig. 9 The results of the liver oil red O staining experiment of compound 17 are shown in FIG. 1 ; wherein: Fig. 9 a is the result of Oil Red O staining experiment of liver in normal group. Fig. 9 b is the experimental result of Oil Red O staining of liver of mice in NASH group; Fig. 9 c is the result of Oil Red O staining experiment of liver treated with compound 17 (0.6 mg / kg); Fig. 9 d is the result of Oil Red O staining experiment of liver treated with compound 17 (2 mg / kg); Fig. 9 e is the result of Oil Red O staining experiment on liver treated with compound 17 (6 mg / kg); Fig. 9 f is the result of Oil Red O staining experiment of liver treated with V022-1200 (10 mg / kg); Fig. 9 g is the result of Oil Red O staining experiment on liver treated with compound OCA (10 mg / kg). DETAILED DESCRIPTION

[0055] The present invention is further described below in conjunction with specific embodiments and drawings, but the protection scope of the present invention is not limited to the following embodiments.

[0056] Example 1: Preparation of Compound 1

[0057] Preparation of ethyl 1-(2-(4-(N-(3-fluorobenzyl)benzamido)phenyl)acetyl)piperidine-4-carboxylate (1)

[0058] Compound 4-aminophenylacetic acid ethyl ester (Ⅲ, 27.89mmol) was added to the reaction flask, and N,N-dimethylformamide (DMF) (50mL) and potassium carbonate (30.69mmol) were added in sequence. After stirring at room temperature for 10min, compound 3-fluorobenzyl bromide (Ⅳ-1, 30.69mmol) was added. The reaction solution was heated to 45-60°C, and the reaction time was 6-12h. After TLC monitoring (petroleum ether: ethyl acetate = 4:1, v / v) the reaction was complete, the reaction solution was allowed to stand at room temperature, poured into 100mL of cold water, extracted with ethyl acetate (60mL×3), the organic phases were combined, washed with saturated NaCl (60mL), dried with anhydrous MgSO4, filtered, and the solvent was evaporated under reduced pressure. Petroleum ether / ethyl acetate was used as the eluent, and column chromatography was used for separation and purification to obtain compound Ⅴ-1 (2-(4-((3-fluorobenzyl)amino)phenyl)ethyl acetate), with a yield of 90%.

[0059] Under nitrogen protection, compound V-1 (1.74 mmol) was dissolved in anhydrous tetrahydrofuran (20 mL), and 4-dimethylaminopyridine (0.87 mmol), triethylamine (3.48 mmol), and benzoyl chloride (VI-1, 2.61 mmol) were added in sequence. The reaction temperature was maintained at 45-60°C and the reaction was carried out for 6 hours. After the reaction was completed by TLC monitoring (petroleum ether: ethyl acetate = 3:1, v / v), tetrahydrofuran was evaporated under reduced pressure, distilled water (30 mL) was added, and ethyl acetate was used for extraction (20 mL×3). The organic phases were combined, washed with saturated sodium chloride (20 mL), dried over anhydrous magnesium sulfate, filtered, and the solvent was evaporated under reduced pressure. Petroleum ether / ethyl acetate was used as the eluent, and the compound VII-1 (2-(4-(N-(3-fluorobenzyl)benzamido)phenyl)ethyl acetate) was obtained by column chromatography separation and purification with a yield of 93%.

[0060] Compound Ⅶ-1 (1.48 mmol) was added to a reaction flask, and 20 mL of anhydrous ethanol was added and stirred to dissolve. After complete dissolution, 0.5 mol / L NaOH ethanol solution (25 mL) was added dropwise. After the addition was complete, the reaction temperature was maintained at 20-40°C for 6-12 hours. The reaction was monitored by TLC (petroleum ether: ethyl acetate = 1:1, v / v). After the reaction was completed, the solvent was evaporated under reduced pressure, water (10 mL) was added, and 1.0 mol / L HCl was slowly added dropwise under an ice-water bath to adjust the pH to 1-2. 30 mL of water was added, and the mixture was extracted with ethyl acetate (20 mL × 3). The organic phases were combined, washed with saturated NaCl (60 mL), dried over anhydrous MgSO4, filtered, the solvent was evaporated under reduced pressure, and dried at 35°C for 4 hours to obtain compound Ⅷ-1. Compound Ⅷ-1 (2-(4-(N-(3-fluorobenzyl)benzamido)phenyl)acetic acid) does not need to be purified and can be directly used in the next step.

[0061] Compound VIII-1 (1.26 mmol) was added to a reaction flask, followed by anhydrous THF (20 mL), 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU) (1.64 mmol), and N,N-diisopropylethylamine (DIPEA) (1.51 mmol). After activation at room temperature for 30 min, compound piperidine-4-carboxylic acid ethyl ester (IX, 1.89 mmol) was added, the temperature was raised to 45-60°C, and the reaction was carried out for 8-12 h. After the reaction was completed by TLC monitoring (petroleum ether: ethyl acetate = 1:1, v / v), the solvent was evaporated under reduced pressure, 80 mL of water was added, and the mixture was extracted with ethyl acetate (50 mL×3). The organic phases were combined, washed with saturated NaCl (50 mL), dried over anhydrous MgSO4, filtered, and the solvent was evaporated under reduced pressure. Petroleum ether / ethyl acetate was used as the eluent, and the compound 1 was separated and purified by column chromatography.

[0062] The physicochemical and spectral data of compound 1 are as follows:

[0063]

[0064] Yellow solid, 1 H NMR (600MHz, DMSO-d6) δ7.38–7.32(m,1H),7.31(d,J=7.0Hz,2H),7.26(t,J=7.3Hz,1H),7.21(t,J=7.4Hz,2H),7.13(d ,J=8.0Hz,1H),7.12–7.07(m,1H),7.07(dd,J=8.7,2.2Hz,1H),7.03(d,J=8.4Hz,2H),7.00(d,J=8.5Hz,2H),5.09(s,2H ),4.16-4.14(m,1H),4.06(q,J=7.1Hz,2H),3.72-3.69(m,1H),3.62-3.53(m,2H),3.01-2.96(m,1H),2.72-2.68(m,1H) ,2.56–2.51(m,1H),1.77-1.75(m,1H),1.63-1.61(m,1H),1.32-1.28(m,1H),1.26-1.22(m,1H),1.17(t,J=7.1Hz,3H). 13C NMR(151MHz,DMSO-d6)δ174.28,170.24,168.72,163.42,141.51,140.91,136.41,134.75,130.83,130.04,129.87,128.83 ,128.22,127.95,124.29,115.02,114.36,60.44,52.79,45.00,40.80,40.54,28.52,27.95,14.53.HRMS(m / z)(ESI):calcd for C 30 H 32 N2O4F[M+H] + :503.2346; found:503.2340.

[0065] Example 2: Preparation of Compound 2

[0066] 1-(2-(4-(N-(3-fluorobenzyl)cyclohexylcarboxamido)phenyl)acetyl)piperidine-4-carboxylic acid ethyl ester (2)

[0067]

[0068] Refer to the preparation method of compound 1, replace the compound benzoyl chloride with cyclohexylcarbonyl chloride, and the other conditions are the same. Compound 2: light yellow jelly, 1 H NMR (600MHz, DMSO-d6) δ7.32(dd,J=14.1,7.8Hz,1H),7.24(d,J=8.1Hz,2H),7.09(d,J=8.3Hz,2H),7.05(dd,J=8.6,2.4Hz,1H),6.98(d,J=7 .6Hz,1H),6.94(d,J=9.9Hz,1H),4.83–4.77(m,2H),4.23–4.21(m,1H),4.05–4.02(m,2H),3.84–3.82(m,1H),3.76–3.74(m,1H),3.69–3.66 (m,1H),3.10–3.05(m,1H),2.75–2.70(m,1H),2.58–2.51(m,1H),2.1 7–2.13(m,1H),1.80–1.78(m,1H),1.70–1.68(m,1H),1.65–1.60(m,4H ),1.51–1.49(m,1H),1.43–1.38(m,2H),1.34–1.29(m,1H),1.27–1.22(m,1H),1.16(t,J=7.1Hz,3H),1.12–1.09(m,1H),0.90–0.84(m,2H).13 C NMR(151MHz,DMSO-d6)δ175.56,174.22,168.79,163.37,141.31,140.87,136.15,130.76,130.53,128.30,124.28,114.95, 114.38,60.40,52.03,45.38,45.10,41.13,40.88,40.53,29.52,28.60,27.97,25.76,25.50,14.50.HRMS(m / z)(ESI):calcd for C 30 H 38 N2O4F[M+H] + :509.2816;found:509.2819.

[0069] Example 3 Preparation of Compound 3

[0070] 1-(2-(4-(4-(4-chloro-N-(3-fluorobenzyl)benzamido)phenyl)acetyl)piperidine-4-carboxylic acid ethyl ester (3)

[0071]

[0072] Refer to the preparation method of compound 1, replace the compound benzoyl chloride with 4-chlorobenzoyl chloride, and the other conditions are the same. Compound 3: light yellow solid, 1 H NMR(600MHz,DMSO-d6)δ7.35–7.31(m,3H),7.28(d,J=8.5Hz,2H),7.11(dd,J=12.8,9.0Hz,2H),7 .05(d,J=8.5Hz,3H),7.01(d,J=8.4Hz,2H),5.09(s,2H),4.16–4.14(m,1H),4.06(q,J=7.1Hz,2H) ,3.72–3.70(m,1H),3.60–3.56(m,2H),3.01–2.97(m,1H),2.72–2.70(m,1H),2.54–2.52(m,1H),1 .77–1.76(m,1H),1.62–1.60(m,1H),1.34–1.30(m,1H),1.25–1.22(m,1H),1.17(t,J=7.1Hz,3H). 13C NMR(151MHz,DMSO-d6)δ174.30,169.22,168.71,163.42,141.19,140.74,135.30,135.02,134.70,130.83,130.75,129 .99,128.33,128.02,124.35,115.08,114.41,60.46,52.77,44.97,40.82,28.47,27.98,14.53.HRMS(m / z)(ESI):calcd for C 30 H 31 N2O4FCl[M+H] + :537.1956; found:537.1949.

[0073] Example 4 Preparation of Compound 4

[0074] 1-(2-(4-(4-(4-ethyl-N-(3-fluorobenzyl)benzamido)phenyl)acetyl)piperidine-4-carboxylic acid ethyl ester (4)

[0075]

[0076] Refer to the preparation method of compound 1, replace the compound benzoyl chloride with 4-ethylbenzoyl chloride, and the other conditions are the same. Compound 4: pink solid, 1 H NMR (600MHz, DMSO-d6) δ7.35–7.31(m,1H),7.23(d,J=8.1Hz,2H),7.12–7.08(m,2H),7.05(d,J=8.5H z,5H),6.99(d,J=8.4Hz,2H),5.08(s,2H),4.16–4.14(m,1H),4.06(q,J=7.1Hz,2H),3.72–3.70(m,1 H),3.63–3.55(m,2H),3.01–2.97(m,1H),2.74–2.69(m,1H),2.56–2.52(m,2H),1.77–1.76(m,1H),1 .63–1.61(m,1H),1.34–1.30(m,1H),1.26–1.19(m,2H),1.17(t,J=7.1Hz,3H),1.09(t,J=7.6Hz,3H). 13C NMR(151MHz,DMSO-d6)δ174.28,170.12,168.76,163.41,146.02,141.77,141.06,134.61,133.67,130.81,129.88,129.15,12 7.82,127.57,124.26,114.99,114.32,60.45,52.92,44.99,40.81,28.50,28.29,27.97,15.52,14.52.HRMS(m / z)(ESI):calcd for C 32 H 36 N2O4F[M+H] + :531.2659; found:531.2651.

[0077] Example 5 Preparation of Compound 5

[0078] 1-(2-(4-(N-(3-fluorobenzyl)-4-methylbenzamido)phenyl)acetyl)piperidine-4-carboxylic acid ethyl ester (5)

[0079]

[0080] Refer to the preparation method of compound 1, replace the compound benzoyl chloride with 4-methylbenzoyl chloride, and the other conditions are the same. Compound 5: yellow solid, 1 H NMR (600MHz, DMSO-d6) δ7.35-7.31(m,1H),7.20(d,J=8.0Hz,2H),7.11(d,J=7.7Hz,1H),7.08(d,J=10.1Hz,1H ),7.04(d,J=8.4Hz,3H),7.01(d,J=7.9Hz,2H),6.99(d,J=8.3Hz,2H),5.08(s,2H),4.13–4.11(m,1H),4.06(q, J=7.1Hz,2H),3.65–3.63(m,1H),3.62-3.55(m,2H),2.97–2.94(m,1H),2.71–2.67(m,1H),2.55–2.51(m,1H),2 .21(s,3H),1.75–1.73(m,1H),1.57–1.55(m,1H),1.34–1.28(m,1H),1.26–1.20(m,1H),1.17(t,J=7.1Hz,3H). 13C NMR(151MHz,DMSO-d6)δ174.29,170.15,168.76,163.41,141.76,141.06,139.87,134.62,133.44,130.80,129.90,129.06,12 8.76,127.84,124.27,115.00,114.32,60.45,52.87,44.99,40.81,40.54,28.50,27.96,21.26,14.53.HRMS(m / z)(ESI):calcd for C 31 H 34 N2O4F[M+H] + :517.2503; found:517.2499.

[0081] Example 6 Preparation of Compound 6

[0082] 1-(2-(4-(4-(4-fluoro-N-(3-fluorobenzyl)benzamido)phenyl)acetyl)piperidine-4-carboxylic acid ethyl ester (6)

[0083]

[0084] Refer to the preparation method of compound 1, replace the compound benzoyl chloride with 4-fluorobenzoyl chloride, and the other conditions are the same. Compound 6: yellow solid, 1 H NMR(600MHz,DMSO-d6)δ7.39-7.36(m,2H),7.35–7.31(m,1H),7.14–7.09(m,2H),7.08–7.03(m ,5H),7.01(d,J=8.4Hz,2H),5.13–5.03(m,2H),4.16–4.14(m,1H),4.06(q,J=7.1Hz,2H),3.73– 3.70(m,1H),3.63-3.59(m,2H),3.02–32.98(m,1H),2.74–2.70(m,1H),2.55–2.52(m,1H),1.7 7–1.76(m,1H),1.63–1.62(m,1H),1.34–1.28(m,1H),1.26–1.22(m,1H),1.17(t,J=7.1Hz,3H). 13C NMR(151MHz,DMSO-d6)δ174.30,169.25,168.71,163.67,162.03,141.43,140.85,134.87,132.85,131.51,131.45,130.82,129.96 ,127.97,124.32,115.28,115.14,115.06,114.51,60.45,52.84,44.98,40.81,40.54,28.51,27.97,14.51.HRMS(m / z)(ESI):calcd for C 30 H 31 N2O4F2[M+H] + :521.2252; found:521.2250.

[0085] Example 7 Preparation of Compound 7

[0086] 1-(2-(4-(N-(3-fluorobenzyl)cyclopropylcarboxamido)phenyl)acetyl)piperidine-4-carboxylic acid ethyl ester (7)

[0087]

[0088] Refer to the preparation method of compound 1, replace the compound benzoyl chloride with cyclopropylcarbonyl chloride, and the other conditions are the same. Compound 7: light yellow jelly, 1 H NMR (600MHz, DMSO-d6) δ7.34-7.30(m,1H),7.25(d,J=8.2Hz,2H),7.17(d,J=8.3Hz,2H),7.05(td,J=8.6,2.4Hz,1 H),6.99(d,J=7.6Hz,1H),6.95(d,J=10.0Hz,1H),4.91-4.84(m,2H),4.23–4.21(m,1H),4.04(q,J=7.1Hz,2H),3.8 6–3.84(m,1H),3.74-3.66(m,2H),3.09–3.04(m,1H),2.73–2.69(m,1H),2.56–2.53(m,1H),1.80–1.78(m,1H),1.7 0–1.68(m,1H),1.37–1.29(m,2H),1.25–1.21(m,1H),1.16(t,J=7.1Hz,3H),0.86–0.83(m,2H),0.67–0.63(m,2H). 13C NMR(151MHz,DMSO-d6)δ174.31,173.09,168.83,161.75,141.24,140.76,130.78,130.60,128.34,124.3 2,115.00,114.41,60.41,52.10,45.10,40.95,28.51,28.04,14.52,12.79,8.69.HRMS(m / z)(ESI):calcd forC 27 H 32 N2O4F[M+H] + :467.2346; found:467.2344.

[0089] Example 8 Preparation of Compound 8

[0090] 1-(2-(4-(N-(3-fluorobenzyl)cyclobutylcarboxamido)phenyl)acetyl)piperidine-4-carboxylic acid ethyl ester (8)

[0091]

[0092] Refer to the preparation method of compound 1, replace the compound benzoyl chloride with cyclobutylcarbonyl chloride, and the other conditions are the same. Compound 8: light yellow jelly, 1 H NMR (600MHz, DMSO-d6) δ7.33–7.29(m,1H),7.21(d,J=8.1Hz,2H),7.04(d,J=7.9Hz,3H),6.99(d,J=7. 7Hz,1H),6.96(d,J=9.8Hz,1H),4.87–4.77(m,2H),4.24–4.22(m,1H),4.04(q,J=7.1Hz,2H),3.85–1.8 3(m,1H),3.74-3.65(m,2H),3.09–3.02(m,2H),2.74–2.68(m,1H),2.58–2.53(m,1H),2.16–2.14(m,2 H),1.80–1.78(m,1H),1.73–1.61(m,5H),1.34–1.30(m,1H),1.23–1.21(m,1H),1.16(t,J=7.1Hz,3H). 13CNMR(151MHz,DMSO-d6)δ174.27,174.12,168.81,161.76,141.21,140.34,136.04,130.75,130.35,128.41,124.34,1 15.02,114.25,60.41,52.07,45.10,40.93,37.88,28.56,28.02,25.70,25.64,17.65,14.51.HRMS(m / z)(ESI):calcd for C 28 H 34 N2O4F[M+H] + :481.2503; found:481.2498.

[0093] Example 9 Preparation of Compound 9

[0094] 1-(2-(4-(N-(3-fluorobenzyl)-3-methoxybenzamido)phenyl)acetyl)piperidine-4-carboxylic acid ethyl ester (9)

[0095]

[0096] Refer to the preparation method of compound 1, replace the compound benzoyl chloride with 3-methoxybenzoyl chloride, and the other conditions are the same. Compound 9: light yellow jelly, 1 H NMR (600MHz, DMSO-d6) δ7.34 (dd, J=14.1, 7.9Hz, 1H), 7.13–7.04 (m, 3H), 7.04–7.00 (m, 5H), 6.88–6. 84(m,2H),6.82(dd,J=8.2,2.1Hz,1H),5.08(s,2H),4.13–4.11(m,1H),4.07(q,J=7.1Hz,2H),3.66– 3.64(m,1H),3.61(s,3H),3.56–3.49(m,2H),2.97–2.93(m,1H),2.70–2.69(m,1H),2.55–2.52(m,1H ),1.75–1.73(m,1H),1.58–1.50(m,1H),1.35–1.29(m,1H),1.26–1.20(m,1H),1.17(t,J=7.1Hz,3H). 13C NMR (151MHz, DMSO-d6) δ174.27,169.90,168.75,163.41,158.92,141.48,140.85,137.63,134.81,130.82,130.77,129.92,129.33,127. 89,124.31,121.12,116.07,115.05,114.16,60.44,60.22,55.49,52.80,44.98,40.80,28.52,27.94,14.53.HRMS(m / z)(ESI):calcdfor C 31 H 34 N2O5F[M+H] + :533.2452; found:533.2458.

[0097] Example 10 Preparation of Compound 10

[0098] 1-(2-(4-(N-(3-fluorobenzyl)-2-methoxybenzamido)phenyl)acetyl)piperidine-4-carboxylic acid ethyl ester (10)

[0099]

[0100] Refer to the preparation method of compound 1, replace the compound benzoyl chloride with 2-methoxybenzoyl chloride, and the other conditions are the same. Compound 10: light yellow solid, 1 H NMR (600MHz, DMSO-d6) δ7.37(dd,J=14.3,7.7Hz,1H),7.22(d,J=7.2Hz,1H),7.17(q,J=7.4Hz,3H),7.08(t, J=8.4Hz,1H),6.97–6.90(m,4H),6.81(t,J=7.4Hz,1H),6.77(d,J=8.3Hz,1H),5.03–4.97(s,2H),4.16–4.1 3(m,1H),4.07(q,J=7.1Hz,2H),3.99(s,3H),3.76–3.74(m,1H),3.58(s,2H),3.03–2.99(m,1H),2.72–2.68 (m,1H),2.55-2.52(m,1H),1.77–1.75(m,1H),1.66–1.64(m,1H),1.30–1.22(m,2H),1.18(t,J=7.1Hz,3H). 13C NMR(151MHz,DMSO-d6)δ174.28,168.71,163.51,161.89,155.04,141.09,140.73,134.98,130.80,130.68,129.19,128.69,127.67,12 6.79,124.01,120.50,114.71,114.21,111.43,60.45,55.59,51.88,44.96,40.74,40.54,28.53,27.93,14.54.HRMS(m / z)(ESI):calcd for C 31 H 34 N2O5F[M+H] + :533.2452; found:533.2457.

[0101] Example 11 Preparation of Compound 11

[0102] 1-(2-(4-(2,6-difluoro-N-(3-fluorobenzyl)benzamido)phenyl)acetyl)piperidine-4-carboxylic acid ethyl ester (11)

[0103]

[0104] Refer to the preparation method of compound 1, replace the compound benzoyl chloride with 2,6-difluorobenzoyl chloride, and the other conditions are the same. Compound 11: yellow solid, 1 H NMR (600MHz, DMSO-d6) δ7.42–7.38(m,1H),7.35–7.30(m,1H),7.14–7.10(m,2H),7.08(d,J=9.8Hz,1H) ,7.05(d,J=8.4Hz,2H),6.98(d,J=8.3Hz,4H),5.09–50.8–5.05(m,2H),4.13–4.11(m,1H),4.07(q,J=7 .1Hz,2H),3.67–3.65(m,1H),3.58–3.56(m,2H),2.97–2.94(m,1H),2.72–2.62(m,1H),2.55–2.51(m,1 H),1.75–1.73(m,1H),1.59–1.57(m,1H),1.32–1.27(m,1H),1.27–1.21(m,1H),1.18(t,J=7.1Hz,3H). 13CNMR(151MHz,DMSO-d6)δ174.27,168.54,163.44,161.82,161.52,157.13,140.06,139.21,136.57,132.34,131.06,131.01,130.09 ,127.35,124.32,115.01,114.86,112.11,111.97,60.45,51.99,44.91,40.78,40.53,28.45,27.94,14.53.HRMS(m / z)(ESI):calcd forC 30 H 30 N2O4F3[M+H] + :539.2158; found:539.2158.

[0105] Example 12 Preparation of Compound 12

[0106] 1-(2-(4-(N-(3-fluorobenzyl)-3-methylbenzamido)phenyl)acetyl)piperidine-4-carboxylic acid ethyl ester (12)

[0107]

[0108] Refer to the preparation method of compound 1, replace the benzoyl chloride with 3-methylbenzoyl chloride, and the other conditions are the same. Compound 12: light yellow jelly, 1 H NMR(600MHz, DMSO-d6)δ7.34(dd,J=14.1,7.9Hz,1H),7.22(s,1H),7.12(d,J=7.7Hz,1H),7.10–7.05(m, 3H),7.04(d,J=8.6Hz,3H),7.00(t,J=8.6Hz,3H),5.08(s,2H),4.16–4.14(m,1H),4.06(q,J=7.1Hz,2H) ,3.73–3.71(m,1H),3.62–3.55(m,2H),3.01–2.97(m,1H),2.72–2.68(m,1H),2.55-2.52(m,1H),2.19(s ,3H),1.77–1.75(m,1H),1.65–1.63(m,1H),1.34–1.30(m,1H),1.25–1.23(m,1H),1.17(t,J=7.1Hz,3H). 13C NMR(151MHz,DMSO-d6)δ174.26,170.28,168.74,163.41,141.55,141.00,137.58,136.30,134.73,130.82,130.76,130.68,129.86,12 9.57,127.91,125.86,124.28,115.01,114.34,60.44,52.80,44.99,40.80,40.55,28.54,27.95,21.23,14.53.HRMS(m / z)(ESI):calcd for C 31 H 34 N2O4F[M+H] + :517.2503; found:517.2504.

[0109] Example 13 Preparation of Compound 13

[0110] 1-(2-(4-(N-(3-fluorobenzyl)cyclopentylcarboxamido)phenyl)acetyl)piperidine-4-carboxylic acid ethyl ester (13)

[0111]

[0112] Referring to the preparation method of compound 1, the compound benzoyl chloride was replaced by cyclopentylcarbonyl chloride, and the other conditions were the same. Compound 13: light yellow jelly, 1 H NMR (600MHz, DMSO-d6) δ7.32(dd,J=14.2,7.8Hz,1H),7.23(d,J=8.1Hz,2H),7.09(d,J=8.2Hz,2H),7.05(dd,J=8.6, 2.3Hz,1H),6.99(d,J=7.6Hz,1H),6.95(d,J=9.8Hz,1H),4.92–4.72(m,2H),4.24–4.21(m,1H),4.04(q,J=6.9Hz,2H) ,3.85–3.83(m,1H),3.75–3.72(m,2H),3.10–3.05(m,1H),2.74–2.69(m,1H),2.59–2.52(m,2H),1.80–1.78(m,1H),1 .70–1.68(m,3H),1.63–1.58(m,2H),1.56–1.54(m,2H),1.35–1.33(m,2H),1.25–1.21(m,2H),1.16(t,J=7.1Hz,3H). 13C NMR(151MHz,DMSO-d6)δ176.05,174.26,168.80,161.75,141.32,140.89,136.13,130.77,130.54,128.57,124.35,115.02, 114.26,60.40,60.22,52.24,45.10,41.79,40.92,31.09,31.05,28.54,28.01,26.24,21.22,14.51.HRMS(m / z)(ESI):calcd for C 29 H 36 N2O4F[M+H] + :495.2659; found:495.2650.

[0113] Example 14 Preparation of Compound 14

[0114] 1-(2-(4-(N-(3-fluorobenzyl)-1-naphthoylamino)phenyl)acetyl)piperidine-4-carboxylic acid ethyl ester (14)

[0115]

[0116] Refer to the preparation method of compound 1, replace benzoyl chloride with 1-naphthoyl chloride, and the other conditions are the same. Compound 14: light yellow jelly, 1 H NMR (600MHz, DMSO-d6) δ7.98 (s, 1H), 7.83 (t, J = 7.5Hz, 2H), 7.71 (d, J = 8.5Hz, 1H), 7.54–7.47 (m, 2H), 7.38–7. 34(m,2H),7.16(dd,J=13.7,8.8Hz,2H),7.10–7.04(m,3H),7.00(d,J=8.4Hz,2H),5.19–5.12(m,2H),4.10–4. 9(m,1H),4.08(p,J=7.2Hz,2H),3.64–3.62(m,1H),3.54(s,2H),2.90–2.88(m,1H),2.70–2.65(m,1H),2.48-2 .45(m,1H),1.74–1.72(m,1H),1.55–1.53(m,1H),1.33–1.27(m,1H),1.25–1.23(m,1H),1.18(t,J=7.1Hz,3H). 13C NMR(151MHz,DMSO-d6)δ174.26,170.20,168.70,163.45,141.46,140.97, 134.78,133.88,133.42,132.36,130.79,129.90,129.17,128.88,128.04 ,127.92,127.74,127.54,127.01,125.70,124.37,115.11,114.53,60.45 ,52.88,44.89,40.75,28.43,27.92,21.72,14.54.HRMS(m / z)(ESI):calcd for C 34 H 33 N2O4NaF[M+Na] + :575.2322; found:575.2327.

[0117] Example 15 Preparation of Compound 15

[0118] 1-(2-(4-((N-(3-fluorobenzyl)-2,3-dihydrobenzofuran)-5-sulfonylamino)phenyl)acetyl)piperidine-4-carboxylic acid ethyl ester (15)

[0119] Compound 4-aminophenylacetic acid ethyl ester (Ⅲ, 27.89mmol) was added to a reaction flask, and N,N-dimethylformamide (DMF) (50mL) and potassium carbonate (30.69mmol) were added in sequence. After stirring at room temperature for 10min, compound 3-fluorobenzyl bromide (Ⅳ-2, 30.69mmol) was added. The reaction solution was heated to 45-60°C, and the reaction time was 6-12h. After TLC monitoring (petroleum ether: ethyl acetate = 4:1, v / v) the reaction was complete, the reaction solution was allowed to stand at room temperature, poured into 100mL of cold water, extracted with ethyl acetate (60mL×3), the organic phases were combined, washed with saturated NaCl (60mL), dried with anhydrous MgSO4, filtered, and the solvent was evaporated under reduced pressure. Petroleum ether / ethyl acetate was used as the eluent, and column chromatography was used for separation and purification to obtain compound V-2 (2-(4-((3-fluorobenzyl)amino)phenyl)ethyl acetate), with a yield of 90%.

[0120] Under nitrogen protection, compound Ⅴ-2 (1.74 mmol) was dissolved in anhydrous tetrahydrofuran (20 mL), and 4-dimethylaminopyridine (0.87 mmol), triethylamine (3.48 mmol), and 2,3-dihydrobenzofuran-5-sulfonyl chloride (Ⅵ-2, 2.61 mmol) were added in sequence. The reaction temperature was maintained at 45-60°C and the reaction was carried out for 6 hours. After the reaction was completed under TLC monitoring (petroleum ether:ethyl acetate=3:1, v / v), tetrahydrofuran was evaporated under reduced pressure, distilled water (30 mL) was added, extracted with ethyl acetate (20 mL×3), the organic phases were combined, washed with saturated sodium chloride (20 mL), dried over anhydrous MgSO4, filtered, and the solvent was evaporated under reduced pressure. Petroleum ether / ethyl acetate was used as eluent, and compound Ⅶ-2 (ethyl acetate 2-(4-((N-(3-fluorobenzyl)-2,3-dihydrobenzofuran)-5-sulfonylamino)phenyl) was separated and purified by column chromatography with a yield of 91%.

[0121] Compound Ⅶ-2 (1.48 mmol) was added to a reaction flask, and 20 mL of anhydrous ethanol was added and stirred to dissolve. After complete dissolution, 0.5 mol / L NaOH ethanol solution (25 mL) was added dropwise. After the addition was complete, the reaction temperature was maintained at 20-40°C for 6-12 hours. The reaction was monitored by TLC (petroleum ether: ethyl acetate = 1:1, v / v). After the reaction was completed, the solvent was evaporated under reduced pressure, water (10 mL) was added, and 1.0 mol / L HCl was slowly added dropwise under an ice-water bath to adjust the pH to 1-2. 30 mL of water was added, and the mixture was extracted with ethyl acetate (20 mL × 3). The organic phases were combined, washed with saturated NaCl (60 mL), dried over anhydrous MgSO4, filtered, the solvent was evaporated under reduced pressure, and dried at 35°C for 4 hours to obtain compound Ⅷ-2 (2-(4-((N-(3-fluorobenzyl)-2,3-dihydrobenzofuran)-5-sulfonamido)phenyl)acetic acid). Compound VIII-2 does not need to be purified and can be directly used in the next reaction.

[0122] Compound VIII-2 (1.26 mmol) was added to a reaction flask, followed by anhydrous THF (20 mL), 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU) (1.64 mmol), and N,N-diisopropylethylamine (DIPEA) (1.51 mmol). After activation at room temperature for 30 min, compound piperidine-4-carboxylic acid ethyl ester (IX, 1.89 mmol) was added, the temperature was raised to 45-60°C, and the reaction was carried out for 8-12 h. After the reaction was completed under TLC monitoring (petroleum ether: ethyl acetate = 1:1, v / v), the solvent was evaporated under reduced pressure, 80 mL of water was added, and the mixture was extracted with ethyl acetate (50 mL×3). The organic phases were combined, washed with saturated NaCl (50 mL), dried over anhydrous MgSO4, filtered, and the solvent was evaporated under reduced pressure. Petroleum ether / ethyl acetate was used as the eluent, and the compound 15 was separated and purified by column chromatography.

[0123] The physicochemical and spectral data of compound 15 are as follows:

[0124]

[0125] Compound 15: pale yellow solid, 1 H NMR (600MHz, DMSO-d6) δ7.53(s,1H),7.32(dd,J=8.5,2.0Hz,1H),7.28(t,J=7.4Hz,1H),7.10(t,J=6.8Hz,3H),7.05(d ,J=9.9Hz,1H),7.00(dd,J=12.8,5.4Hz,3H),6.90(d,J=8.4Hz,1H),4.75(s,2H),4.69–4.66(m,2H),4.20–4.18(m,1H) ,4.05(q,J=7.1Hz,2H),3.80–3.78(m,1H),3.67–3.60(m,2H),3.26–3.23(m,2H),3.06–3.02(m,1H),2.74–2.70(m,1H) ,2.56–2.52(m,1H),1.79–1.77(m,1H),1.69–1.67(m,1H),1.34–1.30(m,1H),1.23–1.22(m,1H),1.16(t,J=7.1Hz,3H). 13 C NMR(151MHz,DMSO-d6)δ174.28,168.76,164.05,163.31,140.04,137.53,135.93,130.76,129.81,129.58,129.46,129.35,128.65,125.23, 124.49,115.17,115.03,114.70,114.57,109.53,72.80,60.43,53.28,45.07,40.87,28.93,28.54,28.00,14.51.HRMS(m / z)(ESI):calcdfor C 31 H 34 N2O6FS[M+H] + :581.2122; found:581.2121.

[0126] Example 16 Preparation of Compound 16

[0127] 1-(2-(4-((N-(3-fluorobenzyl)-4-propylphenyl)sulfonylamino)phenyl)acetyl)piperidine-4-carboxylic acid ethyl ester (16)

[0128]

[0129] Referring to the preparation method of compound 15, the compound 2,3-dihydrobenzofuran-5-sulfonyl chloride was replaced by 4-propylbenzenesulfonyl chloride, and the other conditions were the same. Compound 16: light yellow solid, 1 H NMR (600MHz, DMSO-d6) δ7.53(d,J=8.2Hz,2H),7.42(d,J=8.1Hz,2H),7.29(dd,J=14.2,7.7Hz,1H),7.10(d,J=8.2Hz,3H ),7.04(d,J=9.9Hz,1H),6.99(t,J=10.6Hz,3H),4.78(s,2H),4.20–4.18(m,1H),4.05(q,J=7.1Hz,2H),3.80–3.78(m,1 H),3.67–3.60(m,2H),3.06–3.02(m,1H),2.73-2.69(m,1H),2.68–2.65(m,2H),2.57-2.52(m,1H),1.79–1.77(m,1H),1 .69–1.66(m,1H),1.65–1.60(m,2H),1.34-1.30(m,1H),1.25-1.21(m,1H),1.16(t,J=7.1Hz,3H),0.90(t,J=7.3Hz,3H). 13 C NMR(151MHz,DMSO-d6)δ174.28,168.73,163.30,148.52,139.93,139.88,137.29,136.05,135.55,130.78,130.73,129.85,129.65,128.61,12 7.87,124.48,115.18,115.03,114.76,114.62,60.42,53.33,45.07,40.87,37.39,28.55,27.99,24.10,14.51,13.97.HRMS(m / z)(ESI):calcd for C 32 H 38 N2O5FS[M+H] + :581.2485; found:581.2484.

[0130] Example 17 Preparation of Compound 17

[0131] 1-(2-(4-((N-(3-fluorobenzyl)-2-methoxyphenyl)sulfonylamino)phenyl)acetyl)piperidine-4-carboxylic acid ethyl ester (17)

[0132]

[0133] Referring to the preparation method of compound 15, the compound 2,3-dihydrobenzofuran-5-sulfonyl chloride was replaced by 2-methoxybenzenesulfonyl chloride, and the other conditions were the same. Compound 17: light yellow solid, 1 H NMR (600MHz, DMSO-d6) δ7.61(t,J=7.0Hz,1H),7.56(dd,J=7.8,1.7Hz,1H),7.33(dd,J=14.0,7.9Hz,1H),7.29(d,J=8.2 Hz,1H),7.13(d,J=7.7Hz,1H),7.10–7.05(m,2H),7.04(d,J=2.4Hz,4H),6.97(t,J=7.3Hz,1H),5.11–5.06(m,2H),4.16 –4.13(m,1H),4.05(q,J=7.1Hz,2H),3.73–3.71(m,1H),3.62(s,3H),3.59(s,2H),3.01–2.97(m,1H),2.73–2.68(m,1H) ,2.56–2.51(m,1H),1.77–1.75(m,1H),1.64–1.62(m,1H),1.35–1.30(m,1H),1.25–1.22(m,1H),1.17(t,J=7.1Hz,3H). 13 CNMR(151MHz,DMSO-d6)δ174.27,168.75,163.39,157.02,141.26,137.34,135.72,135.64,131.38,130.83,129.98,128.18,126.74,124.19,1 20.59,114.88,114.73,114.60,114.47,113.38,60.43,56.67,54.81,45.00,40.82,40.55,39.37,28.54,27.96,14.53.HRMS(m / z)(ESI):calcd for C 30 H 34 N2O6FS[M+H] + :569.2122; found:569.2120.

[0134] Example 18 Preparation of Compound 18

[0135] 1-(2-(4-((3,5-difluoro-N-(3-fluorobenzyl)phenyl)sulfonylamino)phenyl)acetyl)piperidine-4-carboxylic acid ethyl ester (18)

[0136]

[0137] Referring to the preparation method of compound 15, the compound 2,3-dihydrobenzofuran-5-sulfonyl chloride was replaced by 3,5-difluorobenzenesulfonyl chloride, and the other conditions were the same. Compound 18: light yellow solid, 1 H NMR (600MHz, DMSO-d6) δ7.74(t,J=9.1Hz,1H),7.35(d,J=4.2Hz,2H),7.33–7.29(m,1H),7.14(d,J=8.4 Hz,2H),7.10(d,J=7.7Hz,1H),7.05(d,J=8.5Hz,4H),4.91–4.84(m,2H),4.20–4.17(m,1H),4.04(q,J= 7.1Hz,2H),3.80–3.78(m,1H),3.69–3.62(m,2H),3.06–3.02(m,1H),2.75–2.68(m,1H),2.56–2.52(m, 1H),1.79–1.77(m,1H),1.68–1.66(m,1H),1.33–1.28(m,1H),1.25–1.19(m,1H),1.15(t,J=7.1Hz,3H). 13 C NMR(151MHz,DMSO-d6)δ174.29,168.74,163.31,163.25,161.69,139.97,137.42,135.98,130.77,130.72,130.05,129.85,129.72,128.62 ,124.47,115.18,115.03,114.92,114.73,114.59,60.43,56.21,53.25,45.07,40.87,40.56,28.55,28.00,14.51.HRMS(m / z)(ESI):calcd for C 29 H 29 N2O5F3NaS[M+Na] + :597.1647; found:597.1652.

[0138] Example 19 Preparation of Compound 19

[0139] 1-(2-(4-((N-(3-fluorobenzyl)-4-methoxyphenyl)sulfonylamino)phenyl)acetyl)piperidine-4-carboxylic acid ethyl ester (19)

[0140]

[0141] Referring to the preparation method of compound 15, the compound 2,3-dihydrobenzofuran-5-sulfonyl chloride was replaced by 4-methoxybenzenesulfonyl chloride, and the other conditions were the same. Compound 19: light yellow solid, 1 H NMR(600MHz,DMSO-d6)δ7.56(d,J=8.9Hz,2H),7.31–7.27(m,1H),7.13–7.09(m,5H),7.05(d,J=10.0 Hz,1H),7.01(dd,J=12.2,5.4Hz,3H),4.76(s,2H),4.20–4.18(m,1H),4.05(q,J=7.1Hz,2H),3.86(s ,3H),3.80–3.78(m,1H),3.67–3.60(m,2H),3.07–3.02(m,1H),2.74–2.69(m,1H),2.57–2.52(m,1H) ,1.79–1.77(m,1H),1.69–1.68(m,1H),1.34–1.30(m,1H),1.25–1.21(m,1H),1.16(t,J=7.1Hz,3H). 13 C NMR(151MHz,DMSO-d6)δ174.29,168.74,163.31,163.25,161.69,139.97 ,139.92,137.42,135.98,130.77,130.72,130.05,129.85,129.72,128.6 2,124.47,115.18,115.03,114.92,114.73,114.59,60.43,56.21,53.25, 45.07,40.87,40.56,39.55,28.55,28.00,14.51.HRMS(m / z)(ESI):calcd for C 30 H 33 N2O6FNaS[M+Na] + :591.1941; found:591.1946.

[0142] Example 20 Preparation of Compound 20

[0143] 1-(2-(4-((2,5-difluoro-N-(3-fluorobenzyl)phenyl)sulfonylamino)phenyl)acetyl)piperidine-4-carboxylic acid ethyl ester (20)

[0144]

[0145] Referring to the preparation method of compound 15, the compound 2,3-dihydrobenzofuran-5-sulfonyl chloride was replaced by 2,5-difluorobenzenesulfonyl chloride, and the other conditions were the same. Compound 20: light yellow jelly, 1 H NMR(600MHz,DMSO-d6)δ7.69–7.65(m,1H),7.61(td,J=9.3,4.1Hz,1H),7.46–7.42(m,1H),7.35–7.31(m,1H ),7.12(d,J=8.6Hz,2H),7.09(t,J=7.3Hz,3H),7.05(d,J=9.1Hz,2H),4.98–4.92(m,2H),4.18–4.16(m,1H), 4.05(q,J=7.1Hz,2H),3.78–3.76(m,1H),3.69–3.60(m,2H),3.06–3.01(m,1H),2.74–2.69(m,1H),2.56–2.5 2(m,1H),1.78–1.77(m,1H),1.67–1.65(m,1H),1.33–1.30(m,1H),1.26–1.23(m,1H),1.16(t,J=7.1Hz,3H). 13 C NMR(151MHz,DMSO-d6)δ174.23,168.66,163.33,161.71,158.52,139.65,136.60,136.26,130.93,130.17,128.71,124.54,123.23,120.21 ,117.80,117.62,115.23,115.09,114.98,114.84,60.41,60.22,53.98,45.02,40.86,39.50,28.49,27.97,14.50.HRMS(m / z)(ESI):calcd for C 29 H 30 N2O5F3S[M+H] + :575.1749; found:575.1746.

[0146] Example 21 Preparation of Compound 21

[0147] 1-(2-(4-((3,4-difluoro-N-(3-fluorobenzyl)phenyl)sulfonylamino)phenyl)acetyl)piperidine-4-carboxylic acid ethyl ester (21)

[0148]

[0149] Referring to the preparation method of compound 15, the compound 2,3-dihydrobenzofuran-5-sulfonyl chloride was replaced by 3,4-difluorobenzenesulfonyl chloride, and the other conditions were the same. Compound 21: light yellow solid, 1 H NMR(600MHz,DMSO-d6)δ7.46(dd,J=10.7,2.0Hz,1H),7.39(dd,J=8.8,1.9Hz,1H),7.35(d,J=7.9Hz ,1H),7.29(d,J=6.2Hz,1H),7.11(t,J=9.1Hz,3H),7.07–6.98(m,4H),4.80(s,2H),4.20–4.18(m,1H ),4.04(q,J=7.1Hz,2H),3.80–3.78(m,1H),3.68–3.61(m,2H),3.07–3.02(m,1H),2.74–2.70(m,1H) ,2.57–2.52(m,1H),1.79–1.77(m,1H),1.69–1.67(m,1H),1.26–1.22(m,2H),1.16(t,J=7.1Hz,3H). 13 C NMR(151MHz,DMSO-d6)δ174.68,169.14,161.71,152.85,151.37,140.27,140.20,137.61,136.62,131.24,131.15,130.34,129.97,129.11 ,126.06,124.93,116.15,115.64,115.38,115.02,65.83,60.84,53.84,45.47,41.30,28.94,28.41,15.24,14.91.HRMS(m / z)(ESI):calcd for C 29 H 29 N2O5F3NaS[M+Na] + :597.1647; found:597.1653.

[0150] Example 22 Preparation of Compound 22

[0151] 1-(2-(4-((3-fluoro-N-(3-fluorobenzyl)phenyl)sulfonylamino)phenyl)acetyl)piperidine-4-carboxylic acid ethyl ester (22)

[0152]

[0153] Referring to the preparation method of compound 15, the compound 2,3-dihydrobenzofuran-5-sulfonyl chloride was replaced by 3-fluorobenzenesulfonyl chloride, and the other conditions were the same. Compound 22: light yellow solid,1 H NMR (600MHz, DMSO-d6) δ7.67(dd,J=13.5,8.0Hz,1H),7.62(dd,J=8.5,2.1Hz,1H),7.49(d,J=8.3Hz,1H),7.44(d,J=7.7H z,1H),7.31(dd,J=14.0,7.9Hz,1H),7.12(t,J=9.6Hz,3H),7.05(d,J=10.0Hz,1H),7.01(d,J=8.4Hz,3H),4.88–4.81(m, 2H),4.120–4.18(m,1H),4.04(q,J=7.2Hz,2H),3.80–3.78(m,1H),3.68–3.61(m,2H),3.07–3.02(m,1H),2.74–2.68(m,1 H),2.57–2.52(m,1H),1.79–1.77(m,1H),1.69–1.67(m,1H),1.34–1.32(m,1H),1.23–1.21(m,1H),1.16(t,J=7.1Hz,3H). 13 C NMR(151MHz,DMSO-d6)δ174.28,168.74,163.31,161.69,154.53,139.88,137.32,136.04,135.79,130.78,130.72,129.88,128.60,128.00 ,127.71,124.49,115.18,115.03,114.75,114.61,60.42,53.30,45.07,40.87,33.85,28.55,27.99,23.90,14.51.HRMS(m / z)(ESI):calcd for C 29 H 30 N2O5F2NaS[M+Na] + :579.1741; found:579.1746.

[0154] Example 23 Preparation of Compound 23

[0155] 1-(2-(4-((N-(3-fluorobenzyl)-4-isopropylphenyl)sulfonylamino)phenyl)acetyl)piperidine-4-carboxylic acid ethyl ester (23)

[0156]

[0157] Referring to the preparation method of compound 15, the compound 2,3-dihydrobenzofuran-5-sulfonyl chloride was replaced by 4-isopropylbenzenesulfonyl chloride, and the other conditions were the same. Compound 23: light yellow solid,1 H NMR (600MHz, DMSO-d6) δ7.56(d,J=8.4Hz,2H),7.48(d,J=8.4Hz,2H),7.29(dd,J=14.1,7.9Hz,1H),7.11(t,J=7.3H z,3H),7.04(d,J=10.1Hz,1H),7.01(d,J=8.4Hz,3H),4.79(s,2H),4.20–4.18(m,1H),4.05(q,J=7.1Hz,2H),3.81– 3.79(m,1H),3.68–3.60(m,2H),3.07–3.02(m,1H),3.01–2.99(m,1H),2.74–2.70(m,1H),2.57–2.52(m,1H),1.79– 1.78(m,1H),1.70–1.68(m,1H),1.36–1.32(m,1H),1.31–1.29(m,1H),1.24(d,J=6.9Hz,6H),1.16(t,J=7.1Hz,3H). 13 C NMR(151MHz,DMSO-d6)δ174.28,168.74,163.30,154.53,139.88,137.32,136.04,135.78,130.78,130.72,129.88,128.60,128.00,12 7.71,124.47,115.18,115.03,114.75,114.61,60.42,53.29,45.06,40.87,33.85,28.55,28.00,23.90,14.51.HRMS(m / z)(ESI):calcd forC 32 H 37 N2O5FNaS[M+Na] + :603.2305; found:603.2310.

[0158] Example 24 Preparation of Compound 24

[0159] 1-(2-(4-((4-(tert-butyl)-N-(3-fluorobenzyl)phenyl)sulfonylamino)phenyl)acetyl)piperidine-4-carboxylic acid ethyl ester (24)

[0160]

[0161] Referring to the preparation method of compound 15, the compound 2,3-dihydrobenzofuran-5-sulfonyl chloride was replaced by 4-tert-butylbenzenesulfonyl chloride, and the other conditions were the same. Compound 24: light yellow solid, 1H NMR (600MHz, DMSO-d6) δ7.62(d,J=8.6Hz,2H),7.57(d,J=8.5Hz,2H),7.29(dd,J=14.1,7.8Hz,1 H),7.11(t,J=7.7Hz,3H),7.07–6.97(m,4H),4.79(s,2H),4.21–4.18(m,1H),4.05(q,J=7.1Hz,2 H),3.82–3.79(m,1H),3.70–3.57(m,2H),3.09–3.03(m,1H),2.76–2.70(m,1H),2.59–2.52(m,1 H),1.81–1.78(m,1H),1.71–1.68(m,1H),1.32(s,9H),1.26–1.24(m,2H),1.16(t,J=7.1Hz,3H). 13 C NMR(151MHz,DMSO-d6)δ174.27,168.73,163.69,156.74,139.85,137.32,136.02,135.55,130.69,129.87,128.58,127.73,12 6.60,124.46,115.20,114.98,60.42,53.28,45.06,40.87,35.41,31.61,31.25,28.55,28.00,14.51.HRMS(m / z)(ESI):calcd forC 33 H 39 N2O5NaSF[M+Na] + :617.2461; found:617.2463.

[0162] Example 25 Preparation of Compound 25

[0163] 1-(2-(4-((N-(4-chlorobenzyl)-2-methoxyphenyl)sulfonylamino)phenyl)acetyl)piperidine-4-carboxylic acid ethyl ester (25)

[0164]

[0165] Referring to the preparation method of compound 15, the compound 3-fluorobenzyl bromide was replaced by 4-chlorobenzyl bromide, and the compound 2,3-dihydrobenzofuran-5-sulfonyl chloride was replaced by 2-methoxybenzenesulfonyl chloride, and the other conditions were the same. Compound 25: light yellow solid, 1HNMR(600MHz,DMSO-d6)δ7.61(t,J=7.1Hz,1H),7.55(dd,J=7.8,1.5Hz,1H),7.34(d,J=8.5Hz,2H),7. 29(d,J=8.6Hz,3H),7.06–6.94(m,5H),4.96(s,2H),4.17–4.14(m,1H),4.07(q,J=7.1Hz,2H),3.99(s, 3H),3.77–3.73(m,1H),3.59(s,2H),3.05–2.99(m,1H),2.74–2.99(m,1H),2.57–2.51(m,1H),1.99(s, 1H),1.78–1.75(m,1H),1.66–1.63(m,1H),1.35–1.30(m,1H),1.27–1.22(m,1H)1.17(t,J=7.1Hz,3H). 13 C NMR(151MHz,DMSO-d6)δ174.27,168.72,157.01,137.26,137.17,135.66,132.31,131.34,130.13,129.92,128.79,128.3 2,126.83,120.56,113.37,60.43,60.21,56.65,54.73,45.00,40.82,28.53,27.97,21.23,14.53.HRMS(m / z)(ESI):calcd for C 30 H 33 N2O6NaSCl[M+Na] + :607.1646; found:607.1641.

[0166] Example 26 Preparation of Compound 26

[0167] 1-(2-(4-((N-(4-(tert-butyl)benzyl)-2-methoxyphenyl)sulfonylamino)phenyl)acetyl)piperidine-4-carboxylic acid ethyl ester (26)

[0168]

[0169] Referring to the preparation method of compound 15, the compound 3-fluorobenzyl bromide was replaced by 4-tert-butylbenzyl bromide, the compound 2,3-dihydrobenzofuran-5-sulfonyl chloride was replaced by 2-methoxybenzenesulfonyl chloride, and the other conditions were the same. Compound 26: light yellow solid, 1H NMR (600MHz, DMSO-d6) δ7.61(d,J=7.3Hz,1H),7.56(dd,J=7.8,1.5Hz,1H),7.30(d,J=8.3Hz,2H),7.27(d,J =8.5Hz,1H),7.19(d,J=8.3Hz,2H),7.05(s,4H),6.97(t,J=7.6Hz,1H),4.94(s,2H),4.16–4.13(m,1H),4.0 6(q,J=7.1Hz,2H),3.98(s,3H),3.77–3.74(m,1H),3.58(s,2H),3.05–3.29(m,1H),2.75–2.69(m,1H),2.57 –2.53(m,1H),1.78–1.75(m,1H),1.67–1.64(m,1H),1.39–1.24(m,2H),1.23(s,9H),1.17(t,J=7.1Hz,3H). 13 C NMR(151MHz,DMSO-d6)δ174.29,168.78,157.01,150.01,137.62,135.59,135.38,135.13,131.36,129.87,128.17,127.81,12 6.91,125.55,120.53,113.34,60.45,56.64,54.95,45.01,40.82,34.65,31.59,28.56,27.99,14.55.HRMS(m / z)(ESI):calcd forC 34 H 42 N2O6NaS[M+Na] + :629.2661; found:629.2660.

[0170] Example 27 Preparation of Compound 27

[0171] 1-(2-(4-((N-(4-fluorobenzyl)-2-methoxyphenyl)sulfonylamino)phenyl)acetyl)piperidine-4-carboxylic acid ethyl ester (27)

[0172]

[0173] Referring to the preparation method of compound 15, the compound 3-fluorobenzyl bromide was replaced by 4-fluorobenzyl bromide, the compound 2,3-dihydrobenzofuran-5-sulfonyl chloride was replaced by 2-methoxybenzenesulfonyl chloride, and the other conditions were the same. Compound 27: white solid, 1H NMR (600MHz, DMSO-d6) δ7.61(t,J=7.1Hz,1H),7.56(dd,J=7.8,1.6Hz,1H),7.29(dd,J=8.4,5.3Hz, 3H),7.10(t,J=8.8Hz,2H),7.06–6.95(m,5H),4.96(s,2H),4.17–4.14(m,1H),4.06(q,J=7.1Hz,2H) ,3.99(s,3),3.77–3.75(m,1H),3.59(s,2H),3.05–3.99(m,1H),2.74–2.68(m,1H),2.57–2.51(m,1H ),1.78–1.76(m,1H),1.67–1.64(m,1H),1.36–1.30(m,1H),1.27–1.24(m,1H)1.17(t,J=7.1Hz,3H). 13 C NMR(151MHz,DMSO-d6)δ174.27,168.73,163.03,157.01,137.26,135.62,134.26,131.32,130.33,130.24,129.88,128.42 ,126.89,120.54,115.68,115.47,113.36,60.43,56.64,54.67,45.01,40.82,28.53,27.97,14.52.HRMS(m / z)(ESI):calcd for C 30 H 33 N2O6NaSF[M+Na] + :591.1941; found:591.1943.

[0174] Example 28 Preparation of Compound 28

[0175] 1-(2-(4-((N-(2,5-difluorobenzyl)-2-methoxyphenyl)sulfonylamino)phenyl)acetyl)piperidine-4-carboxylic acid ethyl ester (28)

[0176]

[0177] Referring to the preparation method of compound 15, the compound 3-fluorobenzyl bromide was replaced by 2,5-difluorobenzyl bromide, and the compound 2,3-dihydrobenzofuran-5-sulfonyl chloride was replaced by 2-methoxybenzenesulfonyl chloride, and the other conditions were the same. Compound 28: yellow solid, 1HNMR(600MHz,DMSO-d6)δ7.62(t,J=7.1Hz,1H),7.53(dd,J=7.8,1.6Hz,1H),7.29(d,J=8.3Hz,1H),7.20– 7.12(m,3H),7.05(q,J=8.6Hz,4H),6.96(t,J=7.6Hz,1H),5.03(s,2H),4.17–4.13(m,1H),4.06(q,J=7.1 Hz,2H),4.00(s,3H),3.76–3.73(m,1H),3.61(s,2H),3.05–2.99(m,1H),2.75–2.69(m,1H),2.57–2.53(m ,1H),1.78–1.75(m,1H),1.67–1.64(m,1H),1.37–1.31(m,2H),1.24–1.22(m,1H),1.17(t,J=7.1Hz,3H). 13 C NMR(151MHz,DMSO-d6)δ174.26,168.71,157.95,157.92,157.02,155.54,155.52,137.16,135.97,135.79,131.40,130.04,128.39,127.16,126 .92,126.54,120.58,117.54,116.26,113.37,60.43,56.69,49.26,45.00,40.81,39.36,28.52,27.94,21.22,14.51.HRMS(m / z)(ESI):calcdfor C 30 H 32 N2O6F2NaS[M+Na] + :609.1847; found:609.1849.

[0178] Example 29 Preparation of Compound 29

[0179] 1-(2-(4-((N-(3-chlorobenzyl)-2-methoxyphenyl)sulfonylamino)phenyl)acetyl)piperidine-4-carboxylic acid ethyl ester (29)

[0180]

[0181] Referring to the preparation method of compound 15, the compound 3-fluorobenzyl bromide was replaced by 3-chlorobenzyl bromide, the compound 2,3-dihydrobenzofuran-5-sulfonyl chloride was replaced by 2-methoxybenzenesulfonyl chloride, and the other conditions were the same. Compound 29: yellow jelly, 1HNMR(600MHz,DMSO-d6)δ7.61(t,J=7.9Hz,1H),7.57(d,J=7.8Hz,1H),7.34–7.24(m,5H),7.08–7 .01(m,4H),6.97(t,J=7.6Hz,1H),5.00(s,2H),4.16–4.13(m,1H),4.06(q,J=7.1Hz,2H),3.99(s ,3H),3.77–3.74(m,1H),3.59(s,2H),3.05–2.99(m,1H),2.75–2.69(m,1H),2.56–2.52(m,1H),1 .78–1.75(m,1H),1.67–1.64(m,1H),1.37–1.30(m,1H),1.27–1.24(m,1H)1.17(t,J=7.1Hz,3H). 13 C NMR(151MHz,DMSO-d6)δ174.25,168.73,157.01,140.81,137.29,135.73,135.65,133.44,131.37,130.71,129.99,128.15,127 .95,127.70,126.82,126.70,120.59,113.37,60.43,56.66,54.71,44.99,40.82,28.54,27.96,14.53.HRMS(m / z)(ESI):calcd for C 30 H 33 N2O6NaSCl[M+Na] + :607.1646; found:607.1647.

[0182] Example 30 Preparation of Compound 30

[0183] 1-(2-(4-((N-(3,4-dichlorobenzyl)-2-methoxyphenyl)sulfonylamino)phenyl)acetyl)piperidine-4-carboxylic acid ethyl ester (30)

[0184]

[0185] Referring to the preparation method of compound 15, the compound 3-fluorobenzyl bromide was replaced by 3,4-dichlorobenzyl bromide, and the compound 2,3-dihydrobenzofuran-5-sulfonyl chloride was replaced by 2-methoxybenzenesulfonyl chloride, and the other conditions were the same. Compound 30: yellow solid, 1HNMR(600MHz,DMSO-d6)δ7.62(t,J=7.1Hz,1H),7.57(d,J=8.2Hz,2H),7.50(d,J=1.7Hz,1H),7.32–7.2 7(m,2H),7.05(q,J=8.6Hz,4H),6.97(t,J=7.6Hz,1H),5.00(s,2H),4.16–4.13(m,1H),4.06(q,J=7.1Hz ,2H),3.99(s,3H),3.77–3.74(m,1H),3.60(s,2H),3.05–2.99(m,1H),2.75–2.69(m,1H),2.56–2.53(m ,1H),1.78–1.75(m,1H),1.67–1.64(m,1H),1.37–1.31(m,1H),1.27–1.24(m,1H)1.17(t,J=7.1Hz,3H). 13 C NMR(151MHz,DMSO-d6)δ174.25,168.72,157.00,139.53,137.17,135.79,131.39,131.09,130.30,130.11,130.06,128 .48,128.14,126.60,120.61,113.38,60.43,56.67,54.16,44.99,40.82,28.52,27.96,14.53.HRMS(m / z)(ESI):calcd for C 30 H 32 N2O6NaSCl2[M+Na] + :641.1256; found:641.1257.

[0186] Example 31 Preparation of Compound 31

[0187] 1-(2-(4-((2-methoxy-N-(4-methylbenzyl)phenyl)sulfonylamino)phenyl)acetyl)piperidine-4-carboxylic acid ethyl ester (31)

[0188]

[0189] Referring to the preparation method of compound 15, the compound 3-fluorobenzyl bromide was replaced by 4-methylbenzyl bromide, the compound 2,3-dihydrobenzofuran-5-sulfonyl chloride was replaced by 2-methoxybenzenesulfonyl chloride, and the other conditions were the same. Compound 31: yellow solid, 1HNMR (600MHz, DMSO-d6) δ7.61(t,J=7.0Hz,1H),7.56(dd,J=7.8,1.6Hz,1H),7.28(d,J=8.2Hz,1H),7.14(d,J= 8.0Hz,2H),7.07(d,J=7.9Hz,2H),7.05–6.94(m,5H),4.91(d,J=1.8Hz,2H),4.17–4.14(m,1H),4.06(q,J=7.1H z,2H),3.98(s,3H),3.77–3.73(m,1H),3.58(s,2H),3.05–2.99(m,1H),2.74–2.69(m,1H),2.57–2.52(m,1H), 2.23(s,3H),1.78–1.76(m,1H),1.67–1.64(m,1H),1.35–1.28(m,1H),1.25–1.23(m,1H)1.17(t,J=7.1Hz,3H). 13 CNMR(151MHz,DMSO-d6)δ174.26,168.75,157.01,137.40,136.80,135.54,135.42,134.94,131.31,129.79,129.33,128.3 8,128.27,127.01,120.51,113.34,60.43,56.61,55.15,45.01,40.81,28.54,27.96,21.11,14.53.HRMS(m / z)(ESI):calcd for C 31 H 36 N2O6NaS[M+Na] + :587.2192; found:587.2190.

[0190] Example 32 Preparation of Compound 32

[0191] 1-(2-(4-((N-(2-chlorobenzyl)-2-methoxyphenyl)sulfonylamino)phenyl)acetyl)piperidine-4-carboxylic acid ethyl ester (32)

[0192]

[0193] Referring to the preparation method of compound 15, the compound 3-fluorobenzyl bromide was replaced by 2-chlorobenzyl bromide, and the compound 2,3-dihydrobenzofuran-5-sulfonyl chloride was replaced by 2-methoxybenzenesulfonyl chloride, and the other conditions were the same. Compound 32: light yellow solid, 1HNMR (600MHz, DMSO-d6) δ7.61(dd,J=8.7,1.7Hz,1H),7.53(dd,J=7.9,1.7Hz,1H),7.38(dd,J=7.6,1.8Hz,1H),7.28(dd,J =11.5,8.7Hz,2H),7.18–7.08(m,2H),7.05(d,J=8.5Hz,1H),7.01(d,J=8.5Hz,1H),6.99–6.93(m,1H),5.04(s,2H),4.18– 4.14(m,1H),4.07(q,J=7.1Hz,2H),4.01(s,3H),3.76–3.73(m,1H),3.64–3.55(m,2H),3.04–2.98(m,1H),2.73–2.68(m,1 H),2.57–2.51(m,1H),1.78–1.75(m,1H),1.66–1.63(m,1H),1.35–1.29(m,1H),1.26–1.24(m,1H),1.18(t,J=7.1Hz,3H). 13 C NMR (151MHz, DMSO-d6) δ174.26,168.70,157.01,137.41,135.76,135.74,135.23,132.64,131.41,130.31,129.96,129.77,129.53 ,128.22,127.71,126.66,120.60,113.37,60.44,56.69,53.22,45.00,40.80,39.36,28.55,27.95,14.53.HRMS(m / z)(ESI):calcd for C 30 H 33 N2O6NaSCl[M+Na] + :607.1646; found:607.1651.

[0194] Example 33 Preparation of Compound 33

[0195] 1-(2-(4-((N-(2-fluorobenzyl)-2-methoxyphenyl)sulfonylamino)phenyl)acetyl)piperidine-4-carboxylic acid ethyl ester (33)

[0196]

[0197] Referring to the preparation method of compound 15, the compound 3-fluorobenzyl bromide was replaced by 2-fluorobenzyl bromide, the compound 2,3-dihydrobenzofuran-5-sulfonyl chloride was replaced by 2-methoxybenzenesulfonyl chloride, and the other conditions were the same. Compound 33: light yellow solid,1 HNMR (600MHz, DMSO-d6) δ7.66–7.57(m,1H),7.58–7.50(m,2H),7.38(dd,J=7.8,1.5Hz,1H),7.31(td,J=8.6,8.0,2 .1Hz,2H),7.26(td,J=7.5,1.8Hz,1H),7.12–7.02(m,4H),6.97(t,J=7.1Hz,1H),5.12(s,2H),4.17–4.14(m,1H),4 .07(q,J=7.1Hz,2H),4.02(s,3H),3.76–3.72(m,1H),3.63–3.55(m,2H),3.04–2.97(m,1H),2.73–2.67(m,1H),2.5 8–2.52(m,1H),1.78–1.75(m,1H),1.66–1.63(m,1H),1.33–1.29(m,1H),1.26–1.24(m,1H),1.18(t,J=7.1Hz,3H). 13 C NMR (151MHz, DMSO-d6) δ174.26,168.70,157.01,137.41,135.76,135.74,135.23,132.64,131.41,130.31,129.96,129.77,129.53 ,128.22,127.71,126.66,120.60,113.37,60.44,56.69,53.22,45.00,40.80,39.36,28.55,27.95,14.53.HRMS(m / z)(ESI):calcd for C 30 H 33 N2O6NaSF[M+Na] + :591.1941; found:591.1946.

[0198] Example 34 Preparation of Compound 34

[0199] 1-(2-(4-((N-(2,6-difluorobenzyl)-2-methoxyphenyl)sulfonylamino)phenyl)acetyl)piperidine-4-carboxylic acid ethyl ester (34)

[0200]

[0201] Referring to the preparation method of compound 15, the compound 3-fluorobenzyl bromide was replaced by 2,6-difluorobenzyl bromide, and the compound 2,3-dihydrobenzofuran-5-sulfonyl chloride was replaced by 2-methoxybenzenesulfonyl chloride, and the other conditions were the same. Compound 34: light yellow solid, 1H NMR (600MHz, CDCl3) δ7.65(dd,J=7.9,1.7Hz,1H),7.54–7.45(m,1H),7.18–7.11(m,1H),7.05(d,J=8. 6Hz,1H),7.04–6.94(m,4H),6.89(t,J=7.6Hz,1H),6.74(t,J=7.8Hz,2H),5.09(s,2H),4.33–4.30(m, 1H),4.12(q,J=7.0Hz,2H),4.02(s,3H),3.63–2.61(m,2H),2.99–2.92(m,1H),2.87–2.80(m,1H),2.4 7–2.40(m,1H),2.05–2.04(s,2H),1.89–1.85(m,1H),1.64–1.52(m,2H),1.25(td,J=7.2,3.4Hz,3H). 13 C NMR (151MHz, CDCl3) δ174.02,168.97,162.91,160.41,156.90,137.01,134.79,134.67,132.05,129.92,129.46,128.75,127.14,120 .26,112.63,111.99,111.25,111.00,60.65,56.11,45.33,43.51,40.87,40.67,28.02,27.60,21.06,14.20.HRMS(m / z)(ESI):calcd for C 30 H 32 N2O6NaSF2[M+Na] + :609.1847; found:609.1845.

[0202] Example 35 Preparation of Compound 35

[0203] 1-(2-(4-((2-methoxy-N-(2-methylbenzyl)phenyl)sulfonylamino)phenyl)acetyl)piperidine-4-carboxylic acid ethyl ester (35)

[0204]

[0205] Referring to the preparation method of compound 15, the compound 3-fluorobenzyl bromide was replaced by 2-methylbenzyl bromide, and the compound 2,3-dihydrobenzofuran-5-sulfonyl chloride was replaced by 2-methoxybenzenesulfonyl chloride, and the other conditions were the same. Compound 35: light yellow jelly, 1H NMR (600MHz, CDCl3) δ7.67 (dd, J=7.8, 1.7Hz, 1H), 7.50 (td, J=7.9, 1.8Hz, 1H), 7.13 (d, J=7.5Hz, 1H), 7 .11–7.03(m,3H),6.99(d,J=8.4Hz,3H),6.93(dd,J=14.2,8.1Hz,3H),5.04–4.95(m,2H),4.32–4.29(m ,1H),4.13(q,J=7.2Hz,4H),3.99(s,3H),3.63–3.59(s,2H),2.99–2.92(m,3.1Hz,1H),2.86–2.79(m,1 H),2.47–2.40(m,1H),2.32(s,3H),1.88–1.85(m,1H),1.64–1.51(m,2H),1.25(td,J=7.2,2.6Hz,3H). 13 C NMR (151MHz, CDCl3) δ174.04,171.19,168.96,156.82,137.67,136.69,134.66,134.37,132.04,130.29,129.79,128.97,128.86,127.55 ,127.32,125.74,120.36,112.03,60.67,60.41,56.07,53.84,45.31,40.67,28.09,27.63,21.07,19.20,14.21.HRMS(m / z)(ESI):calcd forC 31 H 36 N2O6NaS[M+Na] + :587.2192; found:587.2194.

[0206] Example 36 Preparation of Compound 36

[0207] 1-(2-(4-((2-methoxy-N-(3-methylbenzyl)phenyl)sulfonylamino)phenyl)acetyl)piperidine-4-carboxylic acid ethyl ester (36)

[0208]

[0209] Referring to the preparation method of compound 15, the compound 3-fluorobenzyl bromide was replaced by 3-methylbenzyl bromide, and the compound 2,3-dihydrobenzofuran-5-sulfonyl chloride was replaced by 2-methoxybenzenesulfonyl chloride, and the other conditions were the same. Compound 36: light yellow jelly, 1H NMR (600MHz, CDCl3) δ7.71 (dd, J=7.9, 1.7Hz, 1H), 7.50 (td, J=8.5, 1.7Hz, 1H), 7.11 (t, J=7.5Hz, 2H), 7.05–6.99(m,5H),6.97(d,J=8.5Hz,2H),6.92(t,J=7.6Hz,1H),4.97–4.88(m,2H),4.33–4.28(m,1H) ,4.16–4.09(m,4H),3.97(s,3H),3.68–3.59(m,1H),3.59(s,2H),3.02–2.95(m,1H),2.87–2.80(m,1H ),2.48–2.41(m,1H),2.28(s,3H),1.89–1.85(m,1H),1.67–1.60(m,1H),1.25(td,J=7.2,3.7Hz,3H). 13 C NMR (151MHz, CDCl3) δ174.05,171.19,168.96,156.75,137.95,137.82,137.13,134.61,134.30,131.95,129.09,129.00,128.98,128.14 ,127.53,125.48,120.33,111.98,60.66,60.41,56.03,45.33,40.68,40.51,28.09,27.66,21.38,21.07,14.21.HRMS(m / z)(ESI):calcd for C 31 H 36 N2O6NaS[M+Na] + :587.2192; found:587.2196.

[0210] Example 37 Preparation of Compound 37

[0211] 1-(2-(4-((N-(2,5-dichlorobenzyl)-2-methoxyphenyl)sulfonylamino)phenyl)acetyl)piperidine-4-carboxylic acid ethyl ester (37)

[0212]

[0213] Referring to the preparation method of compound 15, the compound 3-fluorobenzyl bromide was replaced by 2,5-dichlorobenzyl bromide, and the compound 2,3-dihydrobenzofuran-5-sulfonyl chloride was replaced by 2-methoxybenzenesulfonyl chloride, and the other conditions were the same. Compound 37: light yellow jelly, 1H NMR (600MHz, CDCl3) δ7.70 (dd, J=7.9, 1.7Hz, 1H), 7.66 (d, J=2.5Hz, 1H), 7.55–7.46 (m, 1H), 7.18 (d, J=8.5Hz,1H),7.16–7.07(m,3H),7.09–7.01(m,3H),6.93(td,J=7.6,1.0Hz,1H),5.14(s,2H),4.34– 4.28(m,1H),4.14–4.09(m,4H),4.01(s,3H),3.68–3.61(m,1H),3.61(s,2H),3.04–2.97(m,1H),2.8 8–2.82(m,1H),2.49–2.41(m,1H),1.90–1.86(m,1H),1.71–1.67(m,1H),1.25(td,J=7.2,3.7Hz,3H). 13 C NMR (151MHz, CDCl3) δ174.03,171.19,168.87,156.73,137.75,136.84,134.95,134.58,133.02,132.10,131.08,130.36,129.68,129 .27,128.63,128.27,126.84,120.46,112.03,60.67,56.10,45.32,41.09,40.68,40.41,28.14,27.65,14.20.HRMS(m / z)(ESI):calcd for C 30 H 32 N2O6NaSCl2[M+Na] + :641.1256; found:641.1260.

[0214] Example 38 Preparation of Compound 38

[0215] 1-(2-(4-((N-(3,5-dichlorobenzyl)-2-methoxyphenyl)sulfonylamino)phenyl)acetyl)piperidine-4-carboxylic acid ethyl ester (38)

[0216]

[0217] Referring to the preparation method of compound 15, the compound 3-fluorobenzyl bromide was replaced by 3,5-dichlorobenzyl bromide, and the compound 2,3-dihydrobenzofuran-5-sulfonyl chloride was replaced by 2-methoxybenzenesulfonyl chloride, and the other conditions were the same. Compound 38: light yellow jelly, 1H NMR(600MHz, CDCl3)δ7.69(dd,J=7.8,1.7Hz,1H),7.56–7.47(m,1H),7.23–7.16(m,3H),7.10–7.01(m,3H ),6.99(d,J=8.5Hz,2H),6.93(td,J=7.6,1.0Hz,1H),4.97–4.87(m,2H),4.34–4.29(m,1H),4.13(q,J=7.1 4H),3.99(s,3H),3.72–3.64(m,1H),3.62(s,2H),3.04–2.97(m,1H),2.88–2.81(m, 1H),2.49–2.42(m,1H),1.90–1.86(m,1H),1.71–1.67(m,1H),1.25(t,J=7.1Hz,3H). 13 C NMR (151MHz, CDCl3) δ174.06,171.20,168.84,156.68,140.97,137.42,134.96,134.90,132.06,129.39,128.81,127.74,126 .92,126.72,120.49,112.07,60.68,56.13,55.16,45.34,41.11,40.67,40.43,28.07,27.69,14.20.HRMS(m / z)(ESI):calcd for C 30 H 32 N2O6NaSCl2[M+Na] + :641.1256; found:641.1259.

[0218] Example 39 Preparation of Compound 39

[0219] 1-(2-(4-((N-benzyl-2-methoxyphenyl)sulfonylamino)phenyl)acetyl)piperidine-4-carboxylic acid ethyl ester (39)

[0220]

[0221] Referring to the preparation method of compound 15, the compound 3-fluorobenzyl bromide was replaced by benzyl bromide, the compound 2,3-dihydrobenzofuran-5-sulfonyl chloride was replaced by 2-methoxybenzenesulfonyl chloride, and the other conditions were the same. Compound 39: light yellow jelly, 1HNMR(600MHz,DMSO-d6)δ7.64–7.58(m,1H),7.56(dd,J=7.8,1.6Hz,1H),7.29(s,1H),7.28–7.25(m,4H),7. 23–7.18(m,1H),7.06–6.99(m,4H),6.97(t,J=7.3Hz,1H),5.02–4.98(m,2H),4.18–4.14(m,1H),4.08–4.03 (m,2H),3.99(s,3H),3.77–3.74(m,1H),3.57(s,2H),3.04–2.98(m,1H),2.74–2.67(m,1H),2.57–2.54(m,1 H),1.78–1.76(m,1H),1.67–1.64(m,1H),1.34–1.29(m,1H),1.25–1.24(m,1H),1.17(td,J=7.1,1.6Hz,3H). 13 C NMR(151MHz,DMSO-d6)δ174.27,170.80,168.75,157.04,138.08,137.46,135.59,135.49,131.35,129.84,128.77,12 8.35,128.25,127.69,126.98,120.54,113.36,60.44,60.22,56.63,45.02,40.82,28.55,27.96,21.22,14.55,14.53.

[0222] HRMS(m / z)(ESI):calcd for C 30 H 35 N2O6S[M+H] + :551.2216; found:551.2216.

[0223] Example 40 Preparation of Compound 40

[0224] 1-(2-(4-((N-(4-isopropylbenzyl)-2-methoxyphenyl)sulfonylamino)phenyl)acetyl)piperidine-4-carboxylic acid ethyl ester (40)

[0225]

[0226] Referring to the preparation method of compound 15, the compound 3-fluorobenzyl bromide was replaced by 4-isopropylbenzyl bromide, the compound 2,3-dihydrobenzofuran-5-sulfonyl chloride was replaced by 2-methoxybenzenesulfonyl chloride, and the other conditions were the same. Compound 40: light yellow jelly, 1H NMR (600MHz, DMSO-d6) δ7.63–7.57(m,1H),7.55(dd,J=7.9,1.7Hz,1H),7.27(d,J=8.0Hz,1H),7.16(q,J=8.3 Hz,4H),7.03(s,4H),6.96(t,J=7.2Hz,1H),4.94(s,2H),4.17–4.14(m,1H),4.08–4.03(m,2H),3.98(s,3H),3 .78–3.74(m,1H),3.59(s,2H),3.05–2.99(m,1H),2.85–2.80(m,1H),2.74–2.68(m,1H),2.57–2.53(m,1H),1. 79–1.76(m,1H),1.67–1.65(m,1H),1.34–1.30(m,1H),1.27–1.24(m,1H),1.19(t,J=7.1Hz,3H),1.15(s,6H). 13 C NMR (151MHz, DMSO-d6) δ174.26,170.79,168.75,157.01,147.73,137.56,135.55,135.39,131.34,129.83,128.23,128.12,126.95,126. 68,120.51,113.32,60.43,60.22,56.61,55.07,45.01,40.81,40.64,33.49,28.55,27.97,24.27,21.22,14.55.HRMS(m / z)(ESI):calcd for C 33 H 41 N2O6S[M+H] + :

[0227] 593.2685; found:593.2695.

[0228] Example 41: FXR agonist activity test

[0229] The present invention tests the agonistic effect of all synthesized compounds on FXR according to the dual luciferase reporter gene detection method. HEK293T cells are seeded in a 96-well white plate at a density of 20,000 / well, and grown overnight at 37°C and 5% CO2 to a density of 50% to 60%, and the culture medium is replaced with serum-free DMEM culture medium. Plasmids pCDNA-FXR, PGL3-FXRE-luc, PRL-TK and Lipo transfection reagent are mixed and placed for 15 minutes, and then the mixture is added to a 96-well plate (10 μL / well) for transfection. After 6 hours of transfection, DMEM culture medium containing 10% fetal bovine serum is replaced, and different concentrations of compounds are added for treatment for 24 hours. After 24 hours, the culture medium is removed, the diluted lysis buffer is added to lyse the cells for 20 minutes, and the cells are centrifuged at 13,000 rpm for 5 minutes, and the supernatant is aspirated and the FXR agonistic activity is measured on an ELISA instrument using a dual luciferase reporter gene detection kit (UElandy). The FXR activation effect of the compound was expressed as the firefly fluorescence value / Renilla fluorescence value, and the half effective concentration (EC) of the compound to stimulate FXR was calculated by nonlinear regression (curve fitting) method. 50 ). The results are shown in Table 1.

[0230] Example 42: Cytotoxicity Assay

[0231] The present invention uses the MTT method to test the cytotoxicity of all synthetic compounds to HepG2 cells and L02 cells. HepG2 and L02 cells are evenly inoculated in a 96-well plate, incubated for 18 hours until the cells adhere to the wall, and then the original culture medium is removed. Drugs with concentrations of 10, 20, 50, 60, 80, 100, 200, and 400 μM are respectively given and cultured in a cell culture incubator for 24 hours. Then 20 μL of MTT solution is added to each well for reaction, and incubated in the dark for 4 hours. After the incubation is completed, the culture medium in the well is aspirated, and 150 μL DMSO is added to each well, and the well is shaken at a low speed to fully dissolve the crystals. The absorbance value of each well is measured at 490 nm. The calculation formula for cell viability is: Cell viability (%) = (OD 待测 -OD 空白 ) / (OD 对照 -OD 空白 )×100. The half inhibitory concentration (IC 50 ). The results are shown in Table 1.

[0232] Table 1 FXR agonist activity and cytotoxicity results of compounds

[0233]

[0234]

[0235] The data are presented as the average of at least three independent repeated experiments. OCA (obeticholic acid) and GW4064 are positive control compounds.

[0236] The results in Table 1 show that the FXR agonist activity of the 40 V022-1200 derivatives synthesized in the present invention is stronger than or close to that of the positive control drugs OCA and GW4064. In addition, compared with the EC 50 The value was 114.210 μM. The derivatives 1, 3, 4, 5, 6, 7, 8, 9, 13, 15, 17, 18, 19, 20, 21 and 22 synthesized by the present invention showed stronger FXR agonist activity. Among them, compound 17 showed the strongest FXR agonist activity (EC 50 =8.44nM), and its activity was increased by 49 times, 27 times and 14 times compared with OCA, GW4064 and V022-1200, respectively, and it is a potent FXR partial agonist. In addition, the compound synthesized by the present invention has no cytotoxicity to HepG2 cells and L02 cells (IC 50 >200 μM). In conclusion, the above data show that the compound synthesized by the present invention has the characteristics of high efficiency and low toxicity.

[0237] Example 43: Determination of triglyceride (TG) content in HepG2 cells, referring to Figure 1 .

[0238] The present invention further determined the effect of the preferred compound 17 on the TG content in HepG2 cells.

[0239] HepG2 cells in the logarithmic growth phase were seeded in a 6-well plate. When the cells were confluent to 80% to 90%, the old culture medium was discarded, and the cells were starved for 16 hours with DMEM culture medium containing 1% bovine serum albumin. 0.6mmol free fatty acids (oleic acid: palmitic acid = 2:1) were added to induce for 12 hours to establish a cell fatty degeneration model. Then different concentrations of compounds were cultured for 24 hours (three replicates were made for each compound). After the compound treatment, 1mL PBS was added to each well to rinse twice, and then 0.25% trypsin was added, centrifuged at 1000 rpm for 5 minutes, and the supernatant was discarded. 1% Triton X-100 lysis solution was added to the cell pellet to lyse the cells for 30 minutes. After sufficient shaking and lysis, 2.5μL of supernatant and 250μL of the mixed triglyceride detection working solution were taken, incubated at 37℃ for 10 minutes, and the absorbance value was detected on an enzyme reader (510nm). The triglyceride content calculation formula is: sample concentration (mmol / gprotein) = (OD 样品 -OD 空白 ) / (OD 标准 -OD 空白)×standard concentration (mmol / L) / protein concentration (g protein / L).

[0240] from Figure 1 It can be seen that compared with the model group, compound 17 (0.05 μM, 0.1 μM) in different concentration groups can significantly reduce the TG content in HepG2 cells, especially 0.05 μM compound 17, which has a better effect on reducing the TG content in cells than the V022-1200 group and the positive control OCA group. The data are expressed as mean ± SEM, compared with the model group, *P ≤ 0.05, **P ≤ 0.01, and ***P ≤ 0.001.

[0241] Example 44: Oil Red O staining experiment, refer to Figure 2 .

[0242] The present invention further uses free fatty acids (FFA) to induce HepG-2 cells to construct a cellular steatosis model, and investigates the effect of compound 17 on improving cellular steatosis.

[0243] HepG2 cells were seeded in a 6-well plate. When the cells were confluent to 80% to 90%, the old culture medium was discarded, and the cells were starved for 16 hours with DMEM culture medium containing 1% bovine serum albumin. 0.6mmol free fatty acids (oleic acid: palmitic acid = 2:1) were added to induce 12 hours to model the cell fatty degeneration model. After the model was successfully established, different concentrations of compounds were used for 24 hours. Then the culture medium in the well plate was removed, washed twice with PBS, fixed with Oil Red O fixative for 25 minutes, washed twice with distilled water, immersed in 60% isopropanol for 3 minutes, and stained with Oil Red O staining solution for 30 minutes. After staining, rinse with 60% isopropanol for 30 seconds, add 1mL of distilled water to each well to keep it moist, and observe under an inverted microscope.

[0244] from Figure 2 It can be seen that compared with the model group, after intervention with different concentrations of compound 17 (0.05 μM, 0.1 μM), the red lipid droplets were significantly improved, especially 0.05 μM compound 17, which had a better effect on improving fatty degeneration than the V022-1200 group and the OCA group. The above data show that compound 17 can significantly improve FFA-induced fatty degeneration of HepG2 cells in vitro.

[0245] Example 45: Anti-NASH pharmacodynamics experiment in mice, refer to Figures 3 to 9 .

[0246] The present invention selects a high-fat and high-sugar diet-induced method to construct a NASH mouse model, thereby investigating the in vivo anti-NASH activity of the preferred compound 17.

[0247] Male 6-week-old C57BL / 6J mice were divided into normal group, model group (NASH group), positive compound OCA group (10 mg / kg), V022-1200 group (10 mg / kg), compound 17 low (0.6 mg / kg), medium (2 mg / kg), and high (6 mg / kg) dose groups, with 10 mice in each group. The normal group was fed with standard feed, and the other groups were fed with high-fat feed and 4% sugar water for 17 consecutive weeks. In the last 4 weeks, the V022-1200 group, OCA group, and the high, medium, and low dose groups of the test compound 17 were gavaged with corresponding doses of drugs. The normal group and the model group were gavaged with an equal amount of 0.5% CMC-Na solution. The mental state of the mice was observed throughout the experimental period, and the weight of the mice was recorded once a week. At the end of the experiment, the mice were fasted for 12 hours without water and food, and blood was collected from the abdominal aorta after the mice were anesthetized with ether. The organs were separated, washed with saline, and weighed and recorded. A biochemical detector was used to measure the biochemical indicators of triglyceride (TG), cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) in the mouse serum, and Oil Red O staining was used to observe the fatty degeneration of the mouse liver.

[0248] from Figures 3 to 8 It can be seen that after 4 weeks of continuous administration, compared with the NASH group, different concentrations of compound 17 can reduce the serum TG, TC, and LDL-C levels of NASH mice and increase the HDL-C level. The medium-dose group (2 mg / kg) of compound 17 is better than the V022-1200 group and the OCA group in reducing the serum TC and LDL-C levels and increasing the HDL-C level of NASH mice. Compared with the NSAH group, the medium-dose group (2 mg / kg) of compound 17 can significantly reduce the levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), and its effect is also better than the V022-1200 group and the OCA group. Fig. 9 It can be seen that compared with the NASH group, different concentrations of compound 17 can improve liver fatty degeneration in mice. The low (0.6 mg / kg) and medium (2 mg / kg) dose groups of compound 17 are better than the V022-1200 group and the OCA group in improving liver fatty degeneration in mice. The data are expressed as mean ± SEM. Compared with the NASH group, *P≤0.05, **P≤0.01, and ***P≤0.001. In short, the above results show that compound 17 can well regulate the blood lipid levels in NASH mice and improve dyslipidemia. Its effect on improving dyslipidemia and liver fatty degeneration is better than OCA.

Claims

1. A compound having the general formula (I) or (II) or a pharmaceutically acceptable salt thereof: in: R1 is selected from any one of the following groups: phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 4-chlorophenyl, 4-ethylphenyl, 4-methylphenyl, 4-fluorophenyl, 2-methoxyphenyl, 3-methoxyphenyl, 2,6-difluorophenyl, 3-methylphenyl, 1-naphthyl; R2, R3, R5 and R6 are each independently selected from hydrogen, methyl or halogen; R4 is selected from hydrogen, methyl, halogen, isopropyl or tert-butyl; R7 is selected from any one of the following groups: 4-propylphenyl, 2-methoxyphenyl, 4-methoxyphenyl, 3,5-difluorophenyl, 2,5-difluorophenyl, 3,4-difluorophenyl, 3-fluorophenyl, 4-isopropylphenyl, 4-tert-butylphenyl, 2. The compound or pharmaceutically acceptable salt according to claim 1, characterized in that: Select any of the following compounds:

3. A method for preparing the compound or a pharmaceutically acceptable salt thereof according to claim 1 or 2, characterized in that: The method for preparing the compound of general formula (I) or a pharmaceutically acceptable salt thereof comprises the following steps: A1. In an organic solvent, ethyl 4-aminophenylacetate of compound III and 3-fluorobenzyl bromide of compound IV-1 are reacted under alkaline conditions to obtain compound V-1 A2. Compound V-1 and Compound VI-1 under alkaline conditions Reaction to obtain compound VII-1 A3. Compound Ⅶ-1 is hydrolyzed in a solvent and alkaline conditions, and then acidified to obtain compound Ⅷ-1 A4. Compound VIII-1 undergoes an amidation reaction with compound IX piperidine-4-carboxylic acid ethyl ester to obtain a compound of formula (I) or a pharmaceutically acceptable salt thereof.

4. A method for preparing the compound or a pharmaceutically acceptable salt thereof according to claim 1 or 2, characterized in that: The preparation method of the compound of general formula (II) or its pharmaceutically acceptable salt comprises the following steps: B1. In an organic solvent, ethyl 4-aminophenylacetate of compound III and compound IV-2 Reaction under alkaline conditions to obtain compound V-2 B2. Compound V-2 and compound VI-2 under alkaline conditions Reaction to obtain compound VII-2 B3. Compound Ⅶ-2 is hydrolyzed in a solvent and alkaline conditions, and then acidified to obtain compound Ⅷ-2 B4. Compound VIII-2 undergoes an amidation reaction with compound IX piperidine-4-carboxylic acid ethyl ester to obtain a compound of formula (II) or a pharmaceutically acceptable salt thereof.

5. The preparation method according to claim 3, characterized in that: In step A1, the molar ratio of the compound III to the compound IV-1 is 1:1-1.5, the reaction temperature is 45-60°C, and the reaction time is 6-12h; the organic solvent is selected from one of anhydrous tetrahydrofuran, N,N-dimethylformamide, dichloromethane, and chloroform, and the alkaline condition is adjusted by adding one of potassium carbonate, sodium carbonate and triethylamine.

6. The preparation method according to claim 3, characterized in that: In step A2, the molar ratio of the compound V-1 to the compound VI-1 is 1:1 to 1.5, the reaction temperature is 45 to 60° C., and the reaction time is 6 to 24 h; the alkaline condition is achieved by adding triethylamine; In step A3, the solvent is one of anhydrous ethanol, methanol and tetrahydrofuran, the alkaline condition is achieved by adding sodium hydroxide or potassium hydroxide, the hydrolysis reaction temperature is 20 to 40° C., and the reaction time is 6 to 12 hours; In step A4, the molar ratio of the compound VIII-1 to the compound IX is 1:1 to 1.5, the reaction temperature is 45 to 60°C, the reaction time is 8 to 12 hours, and the solvent used in the amidation reaction is selected from anhydrous tetrahydrofuran, N,N-dimethylformamide, dichloromethane and chloroform, and the selected condensation agent is 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate and N,N-diisopropylethylamine.

7. The preparation method according to claim 4, characterized in that: In step B1, the molar ratio of the compound III to the compound IV-2 is 1:1-1.5, the reaction temperature is 45-60°C, and the reaction time is 6-12h; the organic solvent is selected from one of anhydrous tetrahydrofuran, N,N-dimethylformamide, dichloromethane, and chloroform, and the alkaline condition is adjusted by adding one of potassium carbonate, sodium carbonate and triethylamine.

8. The preparation method according to claim 4, characterized in that: In step B2, the molar ratio of the compound V-2 to the compound VI-2 is 1:1 to 1.5, the reaction temperature is 45 to 60° C., and the reaction time is 6 to 24 h; the alkaline condition is achieved by adding triethylamine; In step B3, the solvent is one of anhydrous ethanol, methanol and tetrahydrofuran, the alkaline condition is achieved by adding sodium hydroxide or potassium hydroxide, the hydrolysis reaction temperature is 20 to 40° C., and the reaction time is 6 to 12 hours; In step B4, the molar ratio of the compound VIII-2 to the compound IX is 1:1 to 1.5, the reaction temperature is 45 to 60°C, the reaction time is 8 to 12 hours, and the solvent used in the amidation reaction is selected from anhydrous tetrahydrofuran, N,N-dimethylformamide, dichloromethane and chloroform, and the selected condensation agent is 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate and N,N-diisopropylethylamine.

9. A pharmaceutical composition comprising a compound of general formula (I) or (II) according to claim 1 or 2 or a pharmaceutically acceptable salt thereof, or a compound of general formula (I) or a pharmaceutically acceptable salt thereof prepared by the preparation method of claim 3, 5 or 6, or a compound of general formula (II) or a pharmaceutically acceptable salt thereof prepared by the preparation method of claim 4, 7 or 8, and a pharmaceutically acceptable carrier.

10. Use of the compound or pharmaceutically acceptable salt thereof according to claim 1 or 2, or the compound of general formula (I) or pharmaceutically acceptable salt thereof prepared by the preparation method of claim 3, 5 or 6, or the compound of general formula (II) or pharmaceutically acceptable salt thereof prepared by the preparation method of claim 4, 7 or 8, or the pharmaceutical composition according to claim 9 as a farnesoid X receptor partial agonist in the preparation of a medicament for treating farnesoid X receptor-related diseases; preferably, the farnesoid X receptor-related disease is one or more of the following: non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, cholestasis, liver fibrosis, primary biliary cholangitis, and lipid metabolism disorders.